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Phase-transfer catalysis is to facilitate the migration of a reactant from one phase into 
another phase where reaction occurs. Generally, one phase is aqueous and the other is 
organic. Phase-transfer catalyst, usually called PTC, promotes the reaction shuttling 
between two phase. So PTC involves a hydrophilic part like ammonium, phosphonium 
and crown ether for metal ion capture and a liphophilic part like hydrocarbon. According 
to the PTC concept, reactions are performed in heterogeneous two phase systems, that 
offers numerous advantages over traditional methodologies, which use homogeneous 
media, and finds extremely wide application in laboratory organic synthesis and industrial 
processes. Malonates are the structure in that the both ends carbon are in oxidation state 
of +3 and middle carbon in -2 at linear three carbon. Thanks to inherent nature, various 
reactions – Michael addition, Friedel-crafts alkylation, cyclization, Knoevenagel 
condensation, cyclopropanation, cycloaddition and Diels-Alder reaction can be available 
to malonate, which are one of the most fundamental starting materials in diverse research 
areas such as total synthesis, methodology and medicinal chemistry etc. Especially in 
case chirality is added to α-position of malonate, it can become useful building blocks.  
In 2011, our research team reported highly enantioselective synthesis of α,α-
dialkylmalonates by phase-transfer catalytic alkylation using diphenylmethyl tert-butyl 
malonate as a substrate. The results showed excellent yield and ee. By the way, there were 
some problem while hydrolysis for an application. In acidic condition, both esters were 
hydrolyzed and α-chirality was lost. In basic condition, no reaction occurred. We 
developed 2-methylbenzyl tert-butyl malonate as an improved substrate in selective 
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hydrolysis. In case of the substrate selective hydrolysis was possible in basic condition, 
but still both esters were hydrolyzed in acidic condition. And the alkylation results 
showed relatively low enantioselectivity while reactions took long time. For satisfying 
selective hydrolysis in both conditions, excellent reactivity and enantioselectivity, we 
designed benzylideneamino tert-butyl malonate bearing diphenylmethylimine, which is 
originated from the structure of O’donnell substrate. After optimization, we could obtain 
α,α-dialkylmalonates in high chemical (up to 97%) and optical (up to 98% ee) yields 
using (E)-4-bromobenzylideneamino tert-butyl malonate as a final substrate. As an 
application, chiral ε-caprolactone was synthesized and selective hydrolysis in acidic, 
basic and catalytic hydrogenation condition. Also, the enantioselective phase-transfer 
catalytic α-sulfenylation was achieved in high chemical (90%) and optical (92% ee) 
yields using beznhydrylideneamino tert-butyl malonate as a substrate. And the change of 
chiral induction in the asymmetric phase-transfer catalytic alkylation of modified 
substrates through simplification of representative benzylideneamino malonates and 
carbon length-varied malonates was observed. 
Our new catalytic system provided an attractive synthetic method for various chiral 
building blocks that could be readily converted en route to the synthesis of versatile chiral 
target molecules with the involvement of quaternary carbon centers. 
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1. Phase-transfer catalysis 
1-1. Genesis of phase-transfer catalysis 
The phenomenon as known as phase-transfer catalysis was first reported by Walter H. C. 
Rueggeberg in 1946. Rueggeberg researched the optimum for two methods written in the 
literature for synthesizing benzyl benzoate from benzyl chloride and sodium benzoate. 
One method was the reflux of an aqueous solution, the other just phase-transfer catalysis. 
He reported that benzyl benzoate was produced under the tertiary amine-catalyzed 
reaction between sodium benzoate and benzyl chloride in yields of over 90% for about 1 
hour at 110-140ºC (Scheme 1).[1] 
Scheme 1. The first report of phase-transfer catalysis & proposed mechanism 
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Rueggeberg postulated that the tertiary amine-catalyzed reaction proceeds via in situ 
formation of quaternary ammonium intermediates. The theory was based on the fact that 
triethylbenzyl ammonium salts thermally decompose to yield trimethylamine and benzyl 
cation. The fact was supported by the result that using sodium benzoate containing even 
small amounts of benzoic acid, the catalyst was neutralized and the reaction would not 
proceed. Also, through various condition experiments, tertiary amines such as 
triethylamine, N-methylmorpholine, hexamethylenetetramine, and pyridine were all 
effective catalysts. On the other hand, triethanolamine and secondary amines such as 
morpholine were found to be virtually inert, whereas diethylamine exhibited only 
moderate activity. While most of the tertiary amines tried gave good results, 
hexamethylenetetramine and pyridine were found to be less desirable than triethylamine 
or N-methylmorpholine. This was first reported about phase-transfer catalysis, but a bit 
insufficient to be called phase-transfer catalysis be generally known nowadays. 
Organic chemistry reactions worthy of naming phase-transfer catalysis were established 
by Stark, Makosza and Branstrom in the 1960s. Mieczyslaw Makosza, a Polish chemist, 
utilized phase-transfer catalysis to work out various reactions. In 1966, Makosza reported 
that alkylation of indenyl anion with alkyl halides which worked mainly via 
deprotonation with strong bases such as NaNH2, NaH, C6H5Na, Na need rigorously 
anhydrous condition, proceeded in the presence of an aqueous NaOH solution and with 
triethylbenzylammonium chloride as a catalyst, being not inferior in terms of yields to 
classical methods (Scheme 2).[2]  
Scheme 2. Alkylation of indene by phase-transfer catalysis 
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Makosza also reported that alkylarylacetonitriles react with acetylene under conditions 
using NaOH as base, DMSO as solvent, triethylbenzylammonium as catalyst to yield C-
vinylated products (Scheme 3).[3]  
Scheme 3. Vinylation of phenylacetonitrile by phase-transfer catalysis 
Additionally, Makosza reported that nitroarylation(Nucleophilic aromatic substitution) of 
phenylaetonitrile in aqueous medium and alkylation of reissert compound in aqueous 
medium in 1969 (Scheme 4).[4] 
 
Scheme 4. Arylation and additional alkylation of Ar-CH-CN System 
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In 1970, Charles M. Starks introduced the term “phase-transfer catalysis” to explain 
heterogeneous reactions involving anion transfer by quaternary ammonium and 
phosphonium salts.[5] Starks demonstrated that phase-transfer catalysis is a useful and 
versatile tool for the synthesis of diverse organic compounds. Starks reported that 
improved results in terms of yield and reaction time were obtained by using phase-
transfer catalysis in the absence of appropriate mutual solvents such as dimethylsulfoxide 
and dimethylformamide in various reactions - nucleophilic substitution reactions of alkyl 
halides with inorganic anion, dichlorocyclopropanation of alkenes with chloroform and 
aqueous NaOH, oxidation of alkenes with aqueous KMnO4, deuterium exchange of the 
active hydrogens of ketones with D2O, hydrolysis of esters and alkanesulfonyl chlorides 
with aqueous NaOH, and borohydride reduction of ketones (Scheme 5). 
Scheme 5. Diverse phase-transfer catalytic reaction by Starks 
Since then, many organic chemists have studied it and showed an exponential growth of 
phase-transfer catalysis as a practical methodology for organic synthesis. 
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1-2. Mechanism of phase-transfer catalysis 
Mechanism of phase-transfer catalysis was first proposed by Starks.[5] In the simple case 
of the aliphatic nucleophilic substitution of alkyl halides R-X in an aqueous–organic two-
phase system in the presence of catalytic amounts of a quaternary onium salt Q+X− and an 
excess of a metal salt M+Y−, the catalyst transfers the reacting anion Y− into the organic 
phase as lipophilic and unsolvated and therefore a very reactive, ion pair Q+Y− (Figure 
1).[6] 
Figure 1. Starks's extraction mechanism 
In this mechanism, the quaternary ammonium salt having a place in both the aqueous and 
organic phase, transfers the reacting anion from the aqueous to the other phase, at the 
same time the leaving group to the aqueous phase. On the other hand, Dario Landini, a 
Italian chemist, reported that the transport of reacting anion in the other phase does not 
require the concomitant transfer of the quaternary cation through a particular set of 
reaction conditions and the effectiveness of the catalyst depends essentially on its 
lipophilicity through kinetic measurements.[7] Therefore, a modified mechanism was 
proposed. In modified extraction mechanism, the quaternary ammonium purely exists in 




Figure 2. Modified extraction mechanism by Landini's results 
M. Makosza, meanwhile, introduced the interfacial region which was called the phase 
boundary then in 1975 to explain the mechanism.[8] The interfacial region is defined as a 
region of contact of two mutually immiscible phases where, due to the molecular motion, 
there is a gradient of concentration of components of these phases.[9] Makosza proposed 
that the formation of ion-pair between the reacting anion and quaternary ammonium 
occurs on the interfacial region, so does the abstraction of proton in case of reactions 
employing base. 
Figure 3. Makosza's interfacial mechanism 
In Makosza’s mechanism, ion exchange, which occurred in the interfacial region, is 
composed of a few processes: diffusion of the M+Y− and Q+X− from the isotropic region 
of each phase into the interfacial region, formation of ion pair Q+Y− through ion exchange 
in the region, diffusion of the ion pair back to the isotropic region of organic phase 
(Figure 3). Reactions involving reacting anion in situ generated mechanistically much 
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more complicated than phase-transfer catalysis of reacting anion available, because of an 
initial step of deprotonation of the anion precursors. Starks assumed that ammonium 
hydroxide is generated through the ion exchange of Q+X− and M+OH− in the interfacial 
region.[10] However, due to the high hydrophilicity of hydroxide anions the position fo the 
ion exchange equilibrium is unfavorable for Q+OH− and Makosza proposed an alternative 
mechanism that deprotonation takes place in the interfacial region in the direct reaction of 
the carbanion precursor with M+OH− (Figure 4).[9]  
 
Figure 4. Makosza's interfacial mechanism involving deprotonation 
S− generated at the interface cannot migrate into the aqueous phase because of a strong 
salt-out effect of the concentrated aqueous M+OH−, nor into the organic phase because M+ 
is unable to leave the aqueous phase to move with S− into the organic phase. In the 
interfacial region, S− are hardly accessible for nonpolar reagents, show low activity, and, 
what is the most important, due to the very small volume of the region, their 
concentration averaged for the organic phase is negligible. In the presence of a Q+ salt the 
ion exchange takes place to produce lipophilic ion pairs which migrate into the organic 
phase whereas M+X− enters the aqueous phase. In spite of low activity and concentration 
of S− in the interfacial region, the ion exchange, which is diffusion controlled, proceeds at 
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a good rate and assures the concentration of S− in the organic phase being a substantial 
fraction of that of the catalyst.[9]  
As previously stated, mechanism of phase-transfer catalysis was advanced by virtue of 
many hypotheses and experiments. In asymmetric phase-transfer catalysis, Makosza’s 
interfacial mechanism seems to operate. 
 
1-3. Advantages of phase-transfer catalysis 
The advantages of this method are its simple experimental procedures, mild reaction 
conditions, inexpensive and environmentally benign reagents and solvents, and the 
possibility of conducting large-scale preparations. Nowadays, it appears to be the most 
important synthetic method used in various fields of organic chemistry, and has also 
found widespread industrial applications.[11] There are hundreds of industrial applications 
of PTC for a variety of processes of organic synthesis. These technologies always require 
less investment, consume less energy, and generate much less industrial waste as 
compared to the traditional ones. It is obvious that all measures that save energy and 
investment offer directly or indirectly substantial benefits to the environment. Of great 
importance is the direct effect—generation of a smaller volume of waste. The major 
advantages of PTC are listed below:[9] 
 
– Mild reaction condition 
– Use of relatively safe reagents such as K2CO3, NaOH instead of NaH, R2NLi, etc. 
– High reactivity and selectivity of the active species 
– High yields and purity of products. 
– Economical and simple procedures 
19 
 
– Minimization of wastes 
Already numerous and important advantages of PTC are easily recognized in many 
journals and industrial processes. One should stress that when a new synthetic process is 
developed, the possibility of applying PTC should be considered first. Due to the specific 
features of PTC and its advantages presented above it should be considered as a most 
efficient and general green technology.[9] 
 
1-4. Progress of enantioselective phase-transfer catalytic 
alkylation 
The enantioselective alkylation of active methylene compounds occupies the central 
position in the field of asymmetric phase-transfer catalysis, and its development was 
triggered by the pioneering study by a Merck research group in 1984.[12] Dolling and co-
workers reported that the methylation of phenylinanone derivative 1 under liquid-liquid 
phase-transfer catalysis conditions with cinchonine-derived quaternary ammonium salt 2 
was successful to yield the corresponding alkylated product 3 in excellent yield and high 
enantiomeric excess (Scheme 6). 
Scheme 6. First report of asymmetric alkylation by phase-transfer catalysis 
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Dolling proposed the ion pair between quaternary ammonium and deprotonated substrate 
in mechanism. Quinolone ring, C-O bond, N-benzyl group all lie in one plane with CPK 
molecular models, the single-crystal X-ray structure, and molecular modeling studies of 
benzylcinchoninium ion. The quinuclidine ring lies behind the plane. The deprotonated 
form of 1 also has an almost planar structure with the negative charge delocalized into the 
2-phenyl ring. Both molecules in their nearly planar conformations fit naturally on top of 
each other providing π – π stacking interaction between the benzyl group of 2 and the 2-
phenyl group of 1 on the one side and between the quinoline and 3-
methoxydichlorobenzene moieties on the other. The C-hydroxyl in 2 provides a 
directional handle for the ionic attraction via hydrogen bonding to the indanone anion. 
The CH3CI can only alkylate from the front side and form the (S)-2-methylindanone 
(Figure 5).[12] 
 
Figure 5. Ion pair between the catalyst and the substrate proposed by Dolling 
Since then, Martin J. O’Donnell opened on a new chapter in asymmetric phase-transfer 
alkylation reporting the alkylation of Schiff base 4 originated from glycine with 
cinchona-derived quaternary ammonium in 1989.[13] Substrate 2 developed by O’Donnell, 
called O’donnell substrate today, was benzylated under mild condition with N-
(benzyl)cinchoninium chloride (5) as a catalyst, to yield the benzylated product (R)-6 in 
good yield and moderate enantioselectivity. In case of using cinchonidine-derived catalyst 
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ent-5 instead of 5, (S)-6 with the opposite configuration could be obtained with a similar 
degree of yield and enantioselectivity (Scheme 7). The selective monoalkylation without 
the undesired dialkylation was notable, because further alkylation scarcely proceeded for  
the much lower acidity of the remaining α-proton of monoalkylated product 6 compared 
to that of substrate 4 on account of a substantial increase in steric effect of α-position.[14] 
 
Scheme 7. First asymmetric alkylation from glycine derivative 2 by O’Donnell 
 
1-4-1. Development of catalysts for phase-transfer catalytic 
alkylation 
Fundamentally, the development of phase-transfer catalysts for asymmetric alkylation has 
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progressed on the basis of the asymmetric alkylation of the Schiff base from α-amino acid 
such as O’donnell substrate. Representative catalysts from each structure are described as 
follows. 
 
1-4-1-1. Cinchona alkaloid type phase-transfer catalysts 
Cinchona alkaloid derived phase-transfer catalysts, for the first time, was developed of all 
phase-transfer catalysts and have been studied very much. These catalysts could be 
clssified into several sorts depending on a general structure. Monomer series are catalysts 
made by modifying a cinchona alkaloid single molecule with various reactions. Dimer & 
trimer series are synthesized by connecting two or more cinchona alkaloid polymer 
supported series with a linker. Polymeric series are catalysts that generally many single 
molecule catalysts are connected on one macromolecule such as polyethylene glycol 
(PEG), synthetic resins to facilitate reusing catalyst. 
Monomer series are the largest group of cinchona alkaloid derived phase-transfer 
catalysts. They could be distinguishable according to a reagent alkylating nitrogen in 
quinuclidine for forming a quaternary ammonium. Catalysts involving distinctive 
structure, excellent yield and enantioselectivity of them are described as follows (Scheme 
8). Elias James Corey, an American chemist, reported the synthesis of O(9)-Allyl-N-(9-
anthracenylmethyl)cinchonidinium bromide (5a) through N-alkylation with 9-
anthracenylmethyl bromide and O-allylation, and the alkylation utilizing 5a with good 
yield (67-91 %) and excellent enantioselectivity (92-99.5 % ee).[15] Sang-sup Jew & 
Hyeung-geun Park studied electronic factor in N-alkylating agent, employed 2,3,4-
trifluorobenzyl bromide hydrocinchonidine to yield O(9)-Allyl-N-2‘,3‘,4‘-
trifluorobenzylhydrocinchonidinium bromide (5b) involving the alkylation with good 
yield (60-96 %) and excellent enantioselectivity (94->99 % ee).[16] Merrit B. Andrus 
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employed 1,8-difluoro-10-methylanthracene from aryloxazolidinones and aldehydes 
using an efficient electrophilic substitution with phosphorous pentoxide to 5c which 
promoted the alkylation of glycine Schiff base to give the corresponding product in 66-
95 % yield, 96-98% ee.[17] Again Jew & Park synthesized 5d from hydrocinchonidine and 
2-(bromomethyl)pyridine 1-oxide and proposed that 5d forms a rigid conformation by 
coordinating with H2O via hydrogen bonding, which gave the alkylated product with 
excellent yield (86-97 %) and excellent enantioselectivity (97-99 % ee).[18] 
Scheme 8. Cinchona alkaloid type catalysts : monomer 
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Yongmei Wang reported that acetophenone-based cinchona alkaloid-derived quaternary 
ammonium salts (5e) were prepared and evaluated as phase-transfer catalysts in the 
enantioselective alkylation of glycine Schiff base. The alkylation with excellent yield (87-
95 %) and excellent enantioselectivity (85-99 % ee) in short time(2-4 h).[19] Shengyong 
Zhang investigated the electronic and steric influences on enantioselectivities of 
asymmetric phase-transfer reactions, synthesized phase-transfer catalyst 5f from 1-
chloromethyl benzotriazole. Enantioselective alkylations of N-(diphenylmethylene) 
glycine tert-butyl ester (4) were efficiently carried out with various alkyl halides to give 
products in high yields (82-92 %) and enantiomeric excess (94-99% ee).[20] 
Dimer & trimer series are developed mainly by Jew & Park (Scheme 9). In 2001, they 
reported that a dimeric cinchona alkaloid ammonium salt, α,α′-bis[O(9)-
allylcinchonidinium]-m-xylene dibromide (8a), was developed as a new efficient phase-
transfer catalyst and the catalytic enantioselective alkylation of N-
(diphenylmethylene)glycine tert-butyl ester using 8a provided (S)-7 in moderate to good 
yields (50-98 %) and excellent enantioselectivity (90–99% ee).[21] In additional research, 
they synthesized various dimer catalysts in terms of electronic factors and reported the 
alkylation of 4 with 2-F-substituted derivative 8b as a catalyst involving good yields (81-
94 %) and high enantioselectivity (97-99% ee).[22] And they reported that naphthalene-
based dimeric cinchona alkaloids was developed, of which 2,7-naphthalene-based dimeric 
catalysts 8c showed good yields (70-95%) and excellent enantioselectivity (94-99% 
ee).[23] On the other hand, Carmen Najera, a Spanish chemist, synthesized dimeric 
ammonium salts 8d derived from cinchonidine and a bridging (anthracen-9,10-
yl)dimethyl moiety as chiral phase-transfer catalysts to give the alkylated product in 54-
98% yields and 44-86% ee. Najera reported that the counterion generally has a great 
influence on the final enantioselectivity, the hexafluorophosphate anion giving place to 
higher ee’s compared to the chloride or bromide anions.[24] Finally, Jew & Park reported 
the synthesis of α,α′,α′′-tris[O(9)-allylcinchonidinium]mesitylene tribromide 8e and the 
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enantioselective alkylation of 4 using 8e as a catalyst with good yields (65-95%) high 
enantioselectivity (90-97% ee).[25] 
Scheme 9. Cinchona alkaloid type catalysts : dimer & trimer 
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Polymeric series are macromolecule catalysts which low molecular single catalyst is 
synthesized into with various methods (Scheme 10). Polymer-supported is a mostly 
common method of these methods. In 2008, Jew & Park employed Merrifield resin as a 
solid supporting material to synthesize 9a. Alkylation results of 4 were good yields (60-
87 %) and good enantiomeric excess (76-96 % ee). In terms of the reusability, the 5th 
recycle of the catalyst showed slightly reduced enantioselectivity (80%, 94% ee), which 
demonstrates 9a as an efficient and economical polymer supported phase-transfer 
catalyst.[26] Yongmei Wang, on the other hand, synthesized water-soluble PEG-supported 
cinchona ammonium salts 9b. Asymmetric alkylation of 4 in the presence of catalyst 9b 
with various electrophiles in aqueous media showed good yield (77-98%) and good 
enantiomeric excess (82-97% ee).[27] And novel types of polymeric catalyst were 
developed by Shinichi Itsuno. Itsuno reported a phase-transfer catalyst 9c comprising of 
an ionic bond between a chiral catalyst and a polymer, which was synthesized through the 
polymerization of a chiral quaternary ammonium sulfonate monomer or the 
immobilization of a chiral quaternary ammonium salt onto a sulfonated polymer through 
an ion exchange reaction. The alkylated products of 4 using 9c as a catalyst were obtained 
with good yield (45-95%) and good enantiomeric excess (70-98% ee).[28] And in 2010, 
Itsuno reported the synthesis of a novel type of chiral quaternary ammonium polymers, 
which is optically active quaternary ammonium polymers having main chain chirality. 
Catalyst 9d could be reused without loss of reactivity and selectivity through the 
asymmetric benzylation of 4.[29] Also, Itsuno reported a novel type of polymer catalyst 9e 
borrowing conceptions of 9c and 9d, which comprises a quaternary ammonium sulfonate 
repeating unit. Synthesis of 9e consisted of N-benzylation for quaternization of nitrogen 
of quinuclidine and ion-exchange reaction between quaternary ammonium halide and 
sodium sulfonate. The benzylation of 4 in the presence of 9e showed excellent yield (94%) 
and enantiomeric excess (95% ee).[30] 
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9a (20 mol%), 50% aq. KOH
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9b (10 mol%), 1M aq. KOH
Room Temperature
(S)-form, 98%, 83% ee
9d (10 mol%), 50% aq. KOH
Tol/CHCl 3 (7:3), 0oC, 15 h 
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1-4-1-2. Binaphthyl and biphenyl type phase-transfer catalysts 
Binaphthyl and biphenyl type catalysts are artificially synthetic catalysts involving chiral 
axial chirality, which were developed mainly by Keiji Maruoka, a Japanese chemist. In 
2003, Maruoka reported that C2-symmetric chiral quaternary ammonium bromides 10a 
was synthesized from commercially available optically pure 1,1'-bi-2-naphthol as a basic 
chiral unit. The asymmetric alkylation of 4 was conducted with a variety of alkyl halides 
to give the corresponding products in excellent yield (80-98%) and virtually complete 
enantioselectivity (96-99% ee), in which the advantage of the unique N-spiro structure of 
10a and dramatic effect of the steric as well as the electronic properties of the aromatic 
substituents on the 3,3'-position of one binaphthyl moiety had been particularly 
emphasized.[31] And Maruoka report the synthesis of chiral quaternary ammonium salt 
10b to replace the rigid binaphthyl moiety in 10a by flexible straight-chain alkyl groups 
based on the assumption that flexible straight-chain alkyl groups substantially accelerate 
the enolate exchange with 10b because of the increasing polarity of the dialkylammonium 
moiety. Catalysts 10b facilitated catalytic alkylation with high yield (81-98%) and high 
enantioselection (97-98% ee) at very low catalyst loading (0.05 mol %).[32] Maruoka 
designed biphenyl phase-transfer catalysis as well as binaphthyl type, and reported the 
synthesis of 9c and the alkylation using it as a catalyst.[33] Maruoka also developed chiral 
phase-transfer catalyst 10d having a rigid structure with an appropriate dihedral angle by 
possessing a 6,6′-bridged ring on the biphenyl unit. At low catalyst loading benzylation 
with 10d showed excellent yield (94%) and enantioselectivity (95% ee).[34] Finally, 
Maruoka synthesized polyamine-based chiral phase-transfer catalysts 10e based on the 
use of commercially available polyamine frameworks with the expectation of the 
multiplier effect of chiral auxiliaries. The benzylation result with 10e was relatively 
insufficient as compared with results with other catalysts (78%, 83% ee).[35] 
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1-4-1-3. Other type phase-transfer catalysts 
Besides cinchona alkaloid type catalyst from natural compound, binaphtyl and biphenyl 
type catalyst from artificial design, some types phase-transfer catalysts were developed 
and pioneered (Scheme 12). Masakatsu Shibasaki developed tartrate-derived 
diammonium salt 11a through 5 steps from diethyl tartrate. Alkylated products from 4 
were obtained with good yields (71-93%) and good enantioselectivity (80-94 % ee).[36] 
Darren K. MacFarland synthesized else tartrate-derived diammonium salt 1!b in which 
multiple chiral centers are brought together from combining different chiral elements. 
Despite combining many chirality originated from tartaric acid and dimethylpyrroline, the 
alkylation results showed moderate yield (45-84 %, determined by HPLC) and low 
enantioselectivity (8-30 % ee).[37] Kazuo Nagasawa reported that a catalyst 10c, based on 
the parent skeleton of the marine natural product ptilomycalin A, was designed rationally 
to have a C2-symmetric chiral reaction cavity around the substrate recognition/activation 
site (guanidine function). The alkylation of 4 with 11c as a catalyst showed moderate 
yield (55-85 %) and good enantioselectivity (76-90% ee).[38] Kunihiko Takabe 
synthesized a C3 symmetric amine-based chiral phase-transfer catalyst 11d, of which 
application in the benzylation of 4 provided an alkylated product with 55% yield and 58% 
ee.[39] Shinobu Takizawa developed a crown ether 11e involving chirality by spiro 




Scheme 12. Other type phase-transfer catalysts (1) 
On the other hand, Takashi Ooi reported that a P-spiro chiral tetraaminophosphonium salt 
14. Alkylation of azlactones 12 derived from α-amino acids was achieved under solid-
liquid phase-transfer conditions with 63-90% yield and 72-93 % ee.[41] Also, Ooi reported 
the development of a chiral 1,2,3-triazolium salt 17 and its successful application to 
establish the highly enantioselective alkylation of 3-substituted oxindoles (82-99%, 85-98% 
ee) (Scheme 13).[42] 
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1-4-2. Development of substrates for phase-transfer catalytic 
alkylation 
Generally, substrates for phase-transfer catalytic alkylation have an acidic proton for 
deprotonation in reaction mechansim. Then metal hydroxides such as NaOH, KOH and 
CsOH usually were employed as base. In consideration of pKa of metal hydroxides 
(rough 14 to 15) an acidic proton should have lower pKa than 14, which requires that 
substrates have an activating group such as carbonyl group and nitro group in α-position 
of atom which alkylation occurs with. In particular, C-alkylation, an absolute majority of 
phase-transfer catalytic alkylation, needs activating group in α-position of reacting carbon. 
For that reason, substrates for phase-transfer catalytic alkylation have one or more 
activating group, and are classified into three group as follow. 
 
1-4-2-1. Substrates derived from α-amino acid 
α-Amino acid derived substrates naturally have carbonyl group as a part of carboxylic 
acid. This group works as good activating group for lowering pKa of hydrogen of α-
carbon. After glycine Schiff base 4, as previous mentioned, was developed in 1989,[13-14] 
various substrates were developed by many chemists. In case of substrate 4, there are too 
many alkylation results with various activated alkyl halide in various phase-transfer 
catalytic conditions to be described. Instead, some notable applications are described as 
follows (Scheme 14). Maruoka reported that phase-transfer-catalyzed alkylation of 4 with 
racemic secondary alkyl halides proceeded with excellent levels of syn- and 
enantioselectivities under the influence of chiral quaternary ammonium bromide 10f and 
18-crown-6 via an efficient kinetic resolution of racemic secondary alkyl halides in 
2007.[43] In 2011, Maruoka also reported the asymmetric reaction using glycine Schiff 
base 4 and optically pure epoxy triflates proceeded smoothly in the presence of phase-
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Scheme 14. Notable applications of glycine Schiff base 
Many glycine Schiff apart from 4 base were developed (Scheme 15). Ramachandran and 
co-workers reported the use of N,N-diethyl imine glycinamide 4a as substrate for 
asymmetric alkylations using cinchonidinium 5g as a catalyst.[45] Lygo reported the 
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enantioselective alkylation of Schiff base 4b containing benzhydryl etser using a 
quaternary ammonium salt catalyst 10g derived from α-methyl-naphthylamine.[46] 
Kodanko and co-workers developed the enantioselective alkylation of Schiff base 4c 
involving cumyl moiety under cinchona-type catalyst 5a.[47] Maruoka and Takashi 
reported  the enantioselective phase-transfer catalytic alkylation of protected glycine 
amides 4d with the designer chiral quaternary ammonium salt 10h as the catalyst.[48] Also, 
they reported Schiff base 4e containing Weinreb amine, the alkylation of 4e under 
condition of binaphthyl ammonium catalyst 10f.[49] O’Donnell developed resin-bound 
glycine imine 4f, conducted the alkylation in the presence of quaternary ammonium salts 
5a as a catalyst.[50]  
 




In addition to Schiff base for tertiary chiral carbon, Schiff base originated from α-
substituted glycine were developed for quaternary chiral carbon (Scheme 16). Firstly, 
O’Donnell synthesized Schiff base 20 from alanine and conducted the alkylation of 20 in 
the presence of ammonium salt 5h as a catalyst with good yield and low ee.[51] Park and 
Jew reported better alkylation results of 20a containing β-naphthyl group under the 
condition using catalyst 5b.[52] Also, they synthesized ‘-oline’ type substrates (oxazoline 
20b[53], thiazoline 20c[54], imidazoline 20d[55], proline 20e[56]) and conducted alkylation 
using binaphthyl ammonium salt 10a with high yield and enantiomeric excess. Ooi 
reported the alkylation of 20f originated from phenylalanine using 14 as a catalyst.[41] 
Park and Jew reported that resin-supported substrate 20g was synthesized and alkylated in 
the presence of catalyst 5a.[57] 
Scheme 16. α-Amino acid Schiff base for quaternary chiral carbon 
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1-4-2-2. Substrates involving α-position activated by mono-
carbonyl group 
Besides α-amino acid type substrates, various substrates involving mono-carbonyl group, 
which was for the activation of α-position, were synthesized, expanding the boundaries of 
structure for phase-transfer catalytic asymmetric alkylation (Scheme 17). Arai and Shioiri 
designed α-fluorotetralone 21, conducted the asymmetric alkylation of 21 under the 
phase-transfer catalytic condition using 5i.[58] Corey reported that propionic ester 
equivalent 21a was alkylated using cinchona type catalyst 5a.[59] Maruoka synthesized 
oxazolidinone 21b and conducted asymmetric alkylation in the presence of binaphthyl 
type 10j.[60] Ooi used 3-methyloxindole 21c as a substate for asymmetric alkylation, 
reporting chiral 1,2,3-triazoliums 17 as a novel phase-transfer catalyst.[42] Andrus 
designed 2-Acylimidazoles 21d, which was made in three steps from bromoacetic acid. 
Asymmetric alkylation of 21d using cinchona type dimer catalyst 8c was conducted.[61] 
Itoh reported α-cyanocarboxylate 21e as a substrate for asymmetric alkylation. The 
alkylation was performed under phase-transfer condition using chiral spiro ammonium 
10a.[62] Maruoka, also, reported asymmetric alkylation of substrate 21f bearing acetylene 
moieties in the presence of binaphthyl type phase-transfer catalyst 10b.[63] In addition, 
Maruoka presented an asymmetric alkylation of modified 2-arylcyclohexanones 21g that 
employs chiral ammonium bromide 10l as a phase-transfer catalyst.[64] 
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Scheme 17. Substrates involving α-position activated by mono-carbonyl group 
 
1-4-2-3. Substrates involving α-position activated by di-carbonyl 
group 
Many substrates containing α-proton activated by two carbonyl groups were developed 
for phase-transfer catalysis (Scheme 18). Maruoka used cyclic β-keto ester 22 for the 
asymmetric alkylation using ammonium salts 10k as a catalyst.[65] Maruoka, also, 
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developed α-acyl-γ-butyrolactone 22a[66] and cyclic α-amino-β-keto ester 22b[67] and 
conducted the asymmetric alkylation under the condition using 10k. Kim presented the 
development of various tetralone carboxylates 22c and the asymmetric alkylation of 22c 
in the presence of cinchona type catalyst 5j.[68] Park and Jew designed α-tert-butoxy 
carbonyllactams 22d and conducted the asymmetric alkylation of 22d using binaphthyl 
type 10a as a catalyst.[69] Park and Jew, also, developed α-tert-butoxycarbonyllactones 
22e and presented the alkylation of 22e under the phase-transfer catalytic condition using 
10a. 
Scheme 18. Cyclic substrates involving di-carbonyl group 
Apart from substrates involving cyclic structure, various substrates which have linear 
structure were developed (Scheme 19). Maruoka reported the enantioselective alkylation 
of α-fluoro-β-keto ester 23 by asymmetric phase-transfer catalysis using catalyst 10a.[70] 
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In addition, Maruoka developed α-benzoyloxy-β-keto ester 23a and conducted the 
asymmetric alkylation using binaphthyl ammonium 10k.[71] Park and Jew designed N,N-
dialkylmalonamic tert-butyl ester 23b and presented the enantioselective alkylation using 
catalyst 10a. Consecutively they reported α-substituted malonic ester having two different 
esters 23d and asymmetric alkylation using 10a.[72] Also, Itoh independently developed 
non-axisymmetric malonate 23e and conducted the asymmetric alkylation under the 
condition using cinchona type 5k.[73] Jew and Park reported the construction of chiral α-
amino quaternary stereogenic centers under the phase-transfer catalytic condition using 
23f as a substrate and 10a as a catalyst.[74] 





2. α-Chiral malonates 
2-1. Potential of α-Chiral malonates 
Malonates are one of the most fundamental starting materials in organic synthesis.[75] 
They are basically linear three-carbon source but can become easily two- or one-carbon 
source as necessary by simple reactions such as decarboxylation. Because α-position of 
malonate has proper reactivity (pKa ~15), various reactions - Aldol reaction, Michael 
addition, Knoevenagel condensation, Mannich reaction, cycloaddition etc. can be applied 
to establish more complex structure. Thanks to those natures, malonates were widely used 
in total synthesis of natural compounds (Figure 6), e.g. (-)-Sporochnol A,[76] Hirsutine,[77] 
(-)-Przewalskin B,[78] (-)-Debromoflustramine E,[79] (-)-Horsfiline[80] and (-)-
Salinosporamide A.[81] 
 




In case two esters in malonates have different reactivity to each other for different ester 
group etc., α-chiral malonate could be synthesized and diverse chiral compounds could be 
synthesized by converting the ester groups to various other functional groups (Figure 7). 
 
Figure 7. Various modifications of α-chiral malonates 
 
2-2. Asymmetric methodology for α-chiral malonates 
Malonate was utilized in various asymmetric reactions – Michael addition,[82] Friedel-
crafts reaction,[83] Mannich reaction,[84] cyclization,[85] cyclopropanation,[86] Diels-Alder,[87] 
cycloaddition,[88] oxidation and reduction[89] etc. Herein, reactions for granting chirality to 




2-2-1. Asymmetric alkylation 
The research group of Park developed the asymmetric alkylation of α-substituted 
malonates, which involves two different ester moieties (Scheme 20). Park and co-workers 
employed, first, malonic ester 23d with binaphthyl-modified catalyst 10a to obtain α,α-
dialkylmalonate 24a.[72] Additionally, they reported the asymmetric phase-transfer 
catalytic alkylation of α-amidomalonates 23f for α-amino quaternary stereogenic 
centers,[74] α-halo-α-alkylmalonates 23g for α-halo quaternary chiral carbon[90] and 2-
methylbenzyl tert-butyl malonates 23h for selective hydrolysis under basic condition.[91] 
Scheme 20. Asymmetric alkylation through phase-transfer catalyst by Park 
Park and co-workers, also, presented the usefulness of this method to conduct the total 
synthesis of (_)-Horsfiline and (R)-benzylserine (Scheme 21). (_)-Horsfiline, being a 
spriooxindole structure, was isolated in 1991 from the leaves of the Horsfieldia superba 
plant by Bodo et al and has spirooxindole structure. This natural compound could be 
obtained from α-phenyl malonate 25 in 8 steps - asymmetric allylation via phase-transfer 
catalysis, ozonolysis follwed by reductive work-up with triphenylphospine, reduction 
with sodium borohydride, Luche reduction with cerium chloride, tosylation, pyrolidine 
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synthesis, hydrogenation with Pd/C and hydrolysis in acidic condition.[80] (R)-
benzylserine, which is an unnatural amion acid, could be synthesized from 23f in 5 steps 
– enantioselective phase-transfer catalytic benzylation, hydrogenation with Pd/C for ester 
cleavage, azalactonization using chloroformate, reduction with sodium borohydride and 
acidic hydrolysis.[74]  
 
Scheme 21. Application of Park's method (1) : Total synthesis of (-)-horsfiline and (R)-
benzyl serine 
They, also, synthesized a precursor of Welch's (R,R)-HIV-1 protease inhibitor and 
iodolactone 37 as an application (Scheme 22). Welch's (R,R)-HIV-1 protease inhibitor. A 
precursor of Welch's (R,R)-HIV-1 protease inhibitor was obtained via asymmetric phase-
transfer catalytic benzylation, hydrogenation, O-methylation with diazomethane, amide 
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coupling using DCC and HOBT, hydrolysis with trifluoroacetic acid and amide coupling 
with O-benzylated (L)-valine using DCC and HOBT.[90] Optically enriched α-methyl-α-
allylmalonate 35, afforded by asymmetric allylation of 23h, could be successfully 
hydrolyzed to the corresponding acids 36 by 50% KOH. Iodolactonization of 36 with 
iodine in the presence of sodium bicarbonate under a mixture of CHCl3–H2O successfully 
afforded the corresponding iodolactones 37 with 3:1 diastereoselectivity.[91]  
Scheme 22. Application of Park's method (2) : Synthesis of HIV protease inhibitor and 
iodolactone 
Itoh and co-workers reported enantioselective phase-transfer catalytic alkylation of α-
monosubstituted malonic diester 23e (Scheme 23). The alkylation of α-monosubstituted 
tert-butyl methyl malonate 23e in the presence of N-(9-anthracenylmethyl)cinchoninium 
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chloride 5k afforded α,α-disubstituted products in high yields and with high 
enantioselectivities. Moreover, a successful gram-scale (10 mmol) experiment using the 
cinchona catalyst indicates the potential for practical applications of this methodology.[73]  
Scheme 23. Asymmetric alkylation through phase-transfer catalyst by Itoh 
Also, they synthesized of (R)- and (S)-allylphenylalanine through 38 from asymmetric 
allylation of 23e using hydrolysis and curtious rearrangement (Scheme 24). Especially 
each enantiomers of allylphenylalanine were synthesized very efficiently from one 
compound as changing performance sequence of acidic and basic hydrolysis.[73] 
Scheme 24. Application of Itoh's method : Synthesis of (R)- and (S)-allylphenylalanine 
Roger Hunter, in university of Cape Town, reported a new stereoselective alkylation for 
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formation of chiral quaternary centers via a chiral auxiliary protocol involving α-
alkylated malonate imidazolidinones (Scheme 25). Hunter and co-workers conducted the 
asymmetric alkylation of auxiliary-malonate 39 proposing a transition state as shown. 
Scheme 25. Asymmetric alkylation through auxiliary by Hunter 
Also, they conducted a removal of the auxiliary to complete the methodology and an 
application (Scheme 26). Removal of the auxiliary was could be achieved using a 
Fukuyama reduction protocol with minimal dithioester formation by heating with LiSEt 
in THF. Sequently, reduction of thioester 41 with triethylsilane on Pd/C and and reduction 
of aldehyde with sodium borohydride yielded β-hydroxypropionates 42.[92] 





2-2-2. Asymmetric hydrolysis 
Karlheinz Drauz reported the enantioselective hydrolysis of prochiral diester malonates 
using pig liver esterase (PLE) as catalyst (Scheme 27).[93] The best enantioselectivity and 
activity of asymmetric hydrolysis could be achieved with  0.1% of AmmoengTM100, 
ionic liquid, which contains two primary hydroxy groups at the end of two polyethylene 
chains. For the first time, catalytic amounts of hydroxylated and epoxylated ionic liquid 
have been used as additives in enzyme-catalyzed processes, making such processes easier 
to transfer to an industrial scale.[93] 











2-2-3. Asymmetric hydroxylation 
Norio Shibata reported that chiral α-hydroxy malonate 46 could be prepared from 
malonate 45 through α-hydroxylation using oxaziridine and this reaction was catalyzed 
by the (R,R)-DBFOX-Ph/NiII complex (Scheme 28).[89] They presented the first dynamic 
kinetic asymmetric transformation in the α-hydroxylation of racemic malonate to provide 
α-hydroxy quaternary chiral carbon. 
Scheme 28. Asymmetric hydroxylation through DBFOX/NiII catalyst by Shibata 
Also, they demonstrated the utility of α-hydroxy malonate by the synthesis of (R)-
chlozolinate (48), an important antifungal agent (Scheme 29).[89] Chiral α-hydroxy 
malonate 47 was converted to (R)-chlozolinate (48) using 3,5-dichlorophenyl isocyanate 
in the presence of triethylamine. Additionally, they synthesized a key intermediate 52 for 
the bicalutamide, which is sold under the trade name of Casodex, a leading antiandrogen 
used for the treatment of prostate cancer. The chemoselective reduction of 49c was 
successfully achieved using LiAl(Ot-Bu)3H and gave α-hydroxy-propanoate 50 in 66 % 
yield. The primary hydroxy group of 50 was then protected using p-toluenesulfonyl 
chloride and pyridine in CHCl3 to give the tosylate 51. Nucleophilic substitution of 51 by 
sodium 4-fluorobenzenethiol furnished 52, which should be useful as a common 


































































Scheme 29. Applications of Shibata's Method : Synthesis of (R)-chlozolinate and a key 











2-2-4. Asymmetric fluorination 
Shibata and Toru reported that chiral fluoromalonates 54 could be prepared from 
asymmetric fluorination of racemic malonate 53 in the zinc-chiral ligand system (Scheme 
30).[94] They used the method which was modified from previously developed method for 
fluorination of β-keto esters and oxindoles catalyzed by Box-Ph/Cu(OTf)2 or DBFOX-
Ph/Ni(ClO4)2.  
 
Scheme 30. Asymmetric fluorination through DBFOX/Zn catalyst by Shibata and Toru 
They demonstrated the utility of this asymmetric method to present various compounds 
(Scheme 31).[94] The synthesis of fluoro-alacepril (61) was then examined. Alacepril is an 
orally active antihypertensive angiotensin-converting enzyme (ACE) inhibitor, which was 
synthesized in 1978 and launched in Japan in 1988, along with captopril. Structurally, 
alacepril is characterized as a tripeptide-like compound consisting of l-phenylalanine, l-
proline, and 3-mercapto-(2S)-methylpropionic acid. The total synthesis of (S)-fluoro-
Alacepril was accomplished in eight steps starting from chiral malonate 55. 55 was 
treated with LiAl(Ot-Bu)3H in THF followed by tosylation using p-TsCl and pyridine in 
CHCl3 to give 57. The l-proline-containing compound 59 was derived from 57 after 
removal of the tert-butyl ester with TFA, followed by coupling to l-Pro-OtBu under 
standard peptide coupling conditions. Nucleophilic substitution of CH3COSNa followed 
by TFA cleavage of the resulting tert-butyl ester gave 60. Subsequent coupling to l-
phenylalanine tert-butyl ester and TFA treatment afforded fluoro-alacepril (61) in good 
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overall yield. Also, chemoselective reduction of α-fluoro chiral malonate 62 with the 
LiAl(OtBu)3H, followed by tosylation afforded 63. 63 was converted to 64 by amination 
via substitution and acid hydrolysis. 3-fluorinated β-lactam (65) was synthesized by 
intramolecular cyclization of 64 by the Mukaiyama procedure.  





RESULT AND DISCUSSION 
1. Novel malonate substrate for phase-transfer catalysis 
1-1. Previously developed chiral α,α-dialkylmalonates and limits 
Recently, we reported a new synthetic method for chiral α,α-dialkylmalonates through 
phase-transfer catalytic α-alkylation of diphenylmethyl tert-butyl α-alkylmalonate (23d), 
which represents the first reported enantioselective direct catalytic α-alkylation of 
malonates (Scheme 32).[72] The resulting diphenylmethyl tert-butyl α,α-dialkylmalonates 
(24a) could be converted to various versatile chiral intermediates, and they also could be 
successfully applied for the total synthesis of (−)-horsfiline as mentioned in the 
introduction. However, selective removal of the tert-butyl group under acidic conditions 
was not successful due to partial hydrolysis of the diphenylmethyl group for the stability 
of di-benylic carbocation. In alkali basic conditions, the diphenylmethyl ester was not 
selectively hydrolyzed due to steric hindrance from the diphenyl group. 
Scheme 32. First reported asymmetric α-alkylation of malonate and limits in hydrolysis 
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successfully applied for the total synthesis of (−)-horsfiline as mentioned in the 
introduction. However, selective removal of the tert-butyl group under acidic conditions 
was not successful due to partial hydrolysis of the diphenylmethyl group for the stability 
of di-benylic carbocation. In alkali basic conditions, the diphenylmethyl ester was not 
selectively hydrolyzed due to steric hindrance from the diphenyl group. In 2013, we 
developed a new selectively hydrolyzable malonate substrate 23h in alkali basic 
conditions by replacing one of the phenyl groups with a methyl group, and it was 
successfully applied for enantioselective phase-transfer catalytic α-alkylations (Scheme 
33).[91] But, the reaction rate of malonate 23h was too slow (72-168 h) and enantiomeric 
excess was relatively lower than it of 23d (23h : 75~91% ee, 23d : 94~97% ee). Also, 
chirality was still lost in acidic hydrolysis. We needed to develop substrates which satisfy 
good enantioselectivity, alkylation for short time and selective hydrolysis for acidic and 
basic condition. 






1-2. Design and synthesis of benzylideneamino tert-butyl malonate 
We needed to design new malonate substrates possessing an efficient hydrolyzable ester 
group while preserving both a faster reaction rate and a higher enantioselectivity than 
those of 23h. We presumed that the slow reaction rate of 23h might come from the 
decreaesed π–π stacking interactions in the ionic pair between quaternary ammonium 
catalysts 10a and the enolate of malonate 23h which involves the structure removing one 
phenyl group of 23d. The removal of one phenyl group, also, seemed to be responsible 
for the relatively lower enantioselectivity.  
Therefore, we found the way to restore the diphenyl group and reduce the steric hindrance 
in the vicinity of carbonyl carbon on ester. We decided to make the alkyl group of alkoxy 
on diphenylmethyl ester longer. Finally, we designed benzhydrylideneamino malonate 66 
as the new substrate by combining the substrate O’donnell’s substrate for the asymmetric 
synthesis of α-amino acids and our previous malonate substrate 23d (Figure 8). 
Figure 8. Design of novel malonate substrate 
Newly designed substrate 66 was easily synthesized via modified Steglich esterification 
using EDC instead of DDC (Scheme 34). The tert-butanolysis of α-methyl meldrum’s 
acid (67) afforded malonic acid 68. Esterification with carboxylic acid 68 and 
benzophenone oxime 70 derived from benzophenone 69 using EDC in the presence of 4-
dimethylaminopyridine afforded substrate 66. 
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Scheme 34. Synthesis of benzhydrylideneamino tert-butyl malonate 
And the prepared malonate 66 was examined for its efficiency as a substrate by α-
benzylation under typical phase-transfer catalytic conditions based on our previous report 
(Scheme 35). The benzylation data of malonate 66 was better in reaction time (168 h to 4 
h) and enantioselectivity (83% to 88 %) than it of 23h. 
Scheme 29. Comparison of benzylation between novel substrate and improved substrate 
For the definite difference, comparison test was conducted once more by asymmetric 
allylation, of which the enantioselectivity of is generally and significantly lower than that 
of benzylation in PTC alkylation. We thought that allylation is more suitable to accurately 
evaluate comparison (Scheme 36). The allylation of 66 in the presence of catalyst 10a 
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showed 86% chemical yield 71% ee in 5 h. The allylation of 23h under the same PTC 
conditions gave the corresponding allylated products with 57% ee and 80% chemical 
yield in 5 days. Those data demonstrated that the benzhydylideneamino malonate 
substrate (66) showed a much faster reaction rate than that of 2-methylbenzyl malonate 
(23h) with a significantly higher enantioselectivity. 











1-3. Optimization for the enantioselective phase-transfer catalytic 
alkylation of benzylideneamino tert-butyl malonate 
1-3-1. Catalysts screening 
Enantioselective phase-transfer catalytic α-allylation was performed using the 
representative PTCs (Scheme 37). Catalyst 10a showed best results (5 h, 86%, 71% ee). 
Other binaphthyl catalyst 10b afforded greatly decreased enantiomeric excess (13% ee) 
contrary to short reaction time (2 h) and moderate yield (78%). That result suggested that  
binaphthyl group which involves trifluorophenyl group acts an important role in the 
pairing of enolate form of substrate. Cinchona type catalysts generally gave short reaction, 
moderate yield and low enantioselectivity. By the way, allylation products of 5b and 5n, 
which generally give products involving opposite configuration, showed same absolute 
configuration. In case of 5m and 5o, the same phenomenon was seen. These things 
considered it was presumed that malonate 66 form an ion pair different from existing one 
with cinchona type catalysts, that is a cause showing low enantioselectivity. 
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1-3-2. Synthesis and screening of various substrates 
The promising above results prompted us to optimize the structure of the oxime malonate 
substrate to increase the enantioselectivity. Various substrate were synthesized depending 
on the steric and electronic factors (Scheme 38). Ketoxime, derived from ketone and 
aldoxime, derived from aldehyde were obtained by a slightly different method. In case of 
aldoxime and acetophenone (71), E- and Z-form were formed in the ratio different from 





































































































































Scheme 32. Synthesis of benzylideneamino tert-butyl malonate substrates 
Eleven additional tert-butyl malonates were prepared using various oximes, and the 
efficiencies of these substrates were evaluated by phase-transfer catalytic allylation in the 
presence of the best catalyst 10a (Table 1). First we examined the enantioselectivity 
depending cis positioned group. An acetophenone oxime substrate 94 of which cis-phenyl 
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was replaced by methyl group, gave an enantioselectivity that was approximately 10% ee 
lower compared to the benzophenone oxime substrate 66 (94 (entry 2) : 63% ee // 66 
(entry 1) : 71% ee). This result suggeted that methyl group interfered the formation of ion 
pair between catalyst and benzylideneamino substate, which implied that cis position 
does not effect the enantioselectiviy sterically. And, surprisingly, the benzaldehyde oxime 
substrate 95 (entry 3, 71% ee) showed a comparable enantioselectivity to that of the 
benzophenone oxime substrate 66, which contradicts our initial assumption involving the 
π–π stacking interactions of catalyst 10a with diphenyl groups in substrate 23d. We 
refreshingly speculated that the cis-phenyl group of the oxime in substrate 66 might not 
participate the π–π stacking interaction between the substrate and PTC catalyst 10a due to 
its sp2 geometrical conformation in comparison to the sp3 geometrical conformation of 
methyl of 23d. Because aldehyde involving phenyl group substituted with various 
functional group also is more available than ketone, we determined the direction of 
diversification of substrate to benzaldehyde derivatives.  
Table 1. Enantioselective phase-transfer catalytic α-allylation of benzylideneamino tert-
butyl α-methylmalonates[a] 
 
Entry Substrate R1 R2 Product Time (h) Yield (%)[b] ee (%)[c] 
1 66 Ph Ph 66b 5 86 71 
2 94 Ph Me 94b 5 73 63 
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3 95 Ph H 95b 5 81 71 
4 96 1-Nap H 96b 2 50 69 
5 97 2-Nap H 97b 7 77 75 
6 98 4-OMe-Ph H 98b 7 74 71 
7 99 2-F-Ph H 99b 5 56 69 
8 100 3-F-Ph H 100b 4 53 75 
9 101 4-F-Ph H 101b 5 74 78 
10 102 4-Cl-Ph H 102b 6 76 80 
11 103 4-Br-Ph H 103b 5 80 82 
12 104 4-I-Ph H 104b 5 74 80 
[a] Reactions were performed with 5.0 equiv. of allyl bromide and 5.0 equiv. of 50% KOH (aqueous) under the given 
conditions. [b] Isolated yields. [c] Enantioselectivity was determined by HPLC analysis using a chiral column (DAICEL 
Chiralpak AD-H, and AS-H, Chiralcel OD-H, and OJ-H). 
Under the new speculation, additionally nine aldoxime substrates were synthesized was 
alllylated in the phase-transfer catalytic condition with quaternary ammonium 10a. 2-
naphthaldehyde substrate 97 having an increased steric effect showed increased 
enantioselecitvity (entry 5, 75% ee). But 1-naphthaldehyde substrate 96 gave lower yield 
and enantiomeric excess (entry 4, 50%, 69% ee) and 2-Fluorobenzaldehyde substrate 99 
also gave a similar result (entry 7, 56%, 69% ee). These data result from the conformation 
of these substrates (Figure 9). Naphthyl or phenyl group tend to be in one plane with the 
imine for conjugation, that makes the two stable conformation of substrate. But in 
substrate 96, 8-hydrogen on naphthyl group has 1,3-allylic strain with proton of imine. In 
naphthyl-turned conformation, 8-hydrogen has severe steric hinderance for the overlap 
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with the lone pair of nitrogen. In substrate 99, 2-Fluorine is in the same situation. These 
unstable conformations caused the hydrolysis of oxime ester in reaction and the difficulty 
in forming the ion pair with catalyst to show low enantioselectivity.  
Figure 9. The conformation analysis of substrate 96 and 99 
para-methoxy phenyl substrate 98 did not increase the enantioselectivity (entry 6). 
Electro donating group was thought not to be effective on the ion pair with catalyst. 
Halogen substituted phenyl substrates showed increased enantioselectivites. 3- and 4-
fluorophenyl substrate (entry 8, 9) gave increased enantioselectivity (75% ee, 78% ee). In 
4-halogen phenyl substrate, the more period of atom was substituted in para position of 
phenyl, the more enantiomeric excess was increased : F (entry 9: 78% ee) < Cl (entry 10 : 
80% ee) < Br (entry 11 : 82% ee). But 4-iodophenyl substrate 104 showed slightly 
decreased enantiomeric excess (entry12, 80% ee). Therefore, we determined (E)-4-






1-3-3. Screening of base, temperature, solvent  
Next, optimization of the base and temperature conditions was performed using the best 
substrate 103 in the presence of catalyst 10a (Table 2). As shown in Table 2, generally, 
the chemical yield and enantioselectivity did not have a significant dependence on the 
base at 0°C, however, the weak base, K2CO3 showed a longer reaction time (entry 6, 120 
h). A significant decrease in the enantioselectivity was observed in dichloromethane 
(entry 7, 34% ee). As for the temperature, a lower reaction temperature gave a higher 
enantioselectivity : 0°C (entry 2 : 5 h), -20°C (entry 9 : 6 h), -40°C (entry 10 : 9 h). 
However, a significantly longer reaction time was observed at −60 °C (entry 11, 24 h). We 
finally chose the reaction conditions of entry 10 (9 h, 91%, 90% ee) using 50% aqueous 
KOH, under -40°C, toluene as the optimized reaction conditions according to the 







Table 2. Optimization of the reaction conditions[a] 
 
Entry Base Temp. (°C) Solvent Time (h) Yield (%)[b] ee (%)[c] 
1 50% aq. NaOH 0 Toluene 8 75 82 
2 50% aq. KOH 0 Toluene 5 80 82 
3 50% aq. CsOH 0 Toluene 4 55 82 
4 KOH 0 Toluene 1 45 79 
5 CsOH 0 Toluene 0.5 38 80 
6 K2CO3 0 Toluene 120 85 79 
7 50% aq. KOH 0 DCM 24 62 34 
8 50% aq. KOH 0 THF 4 48 54 
9 50% aq. KOH -20 Toluene 6 83 88 
10 50% aq. KOH -40 Toluene 9 91 90 
11 50% aq. KOH -60 Toluene 24 21 87 
[a] Reactions were performed with 5.0 equiv. of allyl bromide and 5.0 equiv. of 50% KOH (aqueous) under the given 
conditions. [b] Isolated yields. [c] Enantioselectivity was determined by HPLC analysis using a chiral column (DAICEL 
Chiralpak AD-H, and AS-H, Chiralcel OD-H, and OJ-H). 
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1-4. Scope and limits of (E)-4-bromobenzylideneamino tert-butyl 
malonate on phase-transfer catalytic alkylation 
Further investigation into the scope and limitations of the alkylating agents was 
performed under the optimized phase-transfer catalytic condition (Table 3). The 
alkylation with allylic halides show high enantioselecitvity (entries 2-5).  2-substituted 
allyl bromide gave an increased enantiomeric excess : Me (entry 3, 94% ee), Br (entry 4, 
93% ee). Also cinnamyl bromide, 1-substituted allyl bromide showed an increased 
enantiomeric excess (entry 5, 95% ee). And a little decreased enantioselecitivity was 
observed in the alkylation of propargyl bromide (entry 6, 85% ee). Straight structure of 
propargyl group was thought no to be favorable in the ion pair approach for the 
asymmetric alkylation. Benzylic bromide presented higher enantioselectivity than allylic 
bromide (entried 1, 7-14). Slightly decreased enantiomeric excesses were observed in the 
asymmetric alkylation with ortho- or meta- substituted benzylic bromide : meta-OMe 
(entry 8, 94% ee), ortho-NO2 (entry 13, 95% ee). 2-naphthyl group, meta and para-
extended benzyl group, also showed a little decreased enantioselectivity (entry 14, 95% 
ee). para-Substituted benzylic bromide except para-iodobenzyl bromide (entry 12, 94% 
ee) presented same or higher enantioselectivity as it of benzyl bromide : para-Me (entry 7, 
98% ee), para-F (entry 9, 97% ee), para-Cl (entry 10, 97% ee), para-Br (entry 11, 98% 
ee). Finally, an unactivated alkylhalide such as hexyl iodide provided a poor chemical 
yield and a moderate enantiomeric excess (entry 15, 0°C, 43%, 79% ee). The high 
enantioselectivities (up to 98% ee) in Table 3 indicate that this reaction method is an 
efficient enantioselective synthetic method for α,α-dialkylmalonates. 
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Table 3. Enantioselective synthesis of α,α-dialkylmalonates via the phase-transfer 
catalytic α-alkylation of 103[a] 
 
Entry RX Product Time (h) Yield (%)[b] ee (%)[c] 
1 
 
103a 7 94 97 
2  103b 9 92 90 
3 
 
103c 12 92 94 
4 
 
103d 12 95 93 
5  103e 8 96 95 





103g 9 97 98 
8 
 
103h 8 90 94 
9 
 
103i 12 91 97 
10 
 
103j 9 94 97 
11 
 
103k 6 90 98 
12 
 
103l 10 95 94 
13 
 
103n 9 90 95 
14 
 
103n 10 94 95 
15[d]  103o 24 43 79 
[a] Reactions were performed with 5.0 equiv. of allyl bromide and 5.0 equiv. of 50% KOH (aqueous) under the given 
conditions. [b] Isolated yields. [c] Enantioselectivity was determined by HPLC analysis using a chiral column (DAICEL 
Chiralpak AD-H, and AS-H, Chiralcel OD-H, and OJ-H). [d] 20.0 equiv. of hexyl iodide and 1.1 equiv. of 50% KOH 
(aquesous) were used at 0°C. 
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1-5. X-ray crystallography for the absolute configuration of 
alkylated products and proposed transition state model 
For confirmation of the absolute configuration, we crystallized p-bromobenzylated 
product 103k and conducted X-ray crystallography analysis (Figure 10). The absolute 
configuration was confirmed as (R)-form.  
 
Figure 10. X-ray crystallographic structure of (R)-103k 
Also, a plausible transition state model was proposed to account for the observed absolute 
configuration of the p-bromobenzylation adduct 103k based on the previously reported 
DFT-based conformational analysis.[95] The malonate enolate anion forms an ionic 
complex with catalyst 10a and then, p-bromobenzyl bromide might approach from the 
sterically less hindered upper side leading to the alkylated adduct 103k with the observed 


















1-6. Applications of phase-transfer catalytic alkylated products 
1-6-1. Synthesis of ε-caprolactone 
As an application, chiral ε-caprolactone (107) was synthesized (Scheme 39). Optically 
enriched α-methyl-α-allylmalonate (130b) was hydrolyzed to the corresponding acid 105 
in a 98% yield by 1N KOH. Allyl ester formation from 105 using allyl bromide in the 
presence of triethylamine in acetonitrile, followed by ring metathesis successfully 
afforded the corresponding chiral ε-caprolactone (107) that is normally hard to obtain by 
the direct phase-transfer catalytic methylation of the corresponding α-carboxylactones.[96] 
 








1-6-2. Selective hydrolysis in acidic and basic condition 
We confirmed the selective hydrolysis, the objective of designing the new malonate 
substrate, in alkali basic and TFA acidic conditions (Scheme 40). We found that the tert-
butyl ester of α-methyl-α-benzylmalonate (103a) was selectively hydrolyzed to the 
corresponding acid (108) in the presence of trifluoroacetic acid in dichloromethane at 0°C, 
which was not possible in the case of the previous substrates (23d, 23f, 23g, 23h). The 
selective hydrolysis of p-bromobenzyloxime ester, also, was successfully accomplished to 
afford the corresponding acid 109 in a 98% yield by 1 N KOH  Fortunately, Monoacid 
(109) could be also obtained by catalytic hydrogenation in the presence of Pd/C under 1 
atm of H2. 







2. Further study of malonate for phase-transfer catalysis 
2-1. Enantioselective phase-transfer catalytic α-sulfenylation 
We conducted as further studies in order to search for other asymmetric phase-transfer 
catalytic reactions which is applicable in benzylieneamino tert-butyl malonate system. 
After various reactions were performed, we developed the enantioselective phase-transfer 
catalytic α-sulfenylation (Scheme 41). This reaction gave the best result in the condition 
using benzhydrylideneamino malonate 66 as a substrate, hydroquininium 5m as a catalyst 
and N-(hexylthio)phthalimide as a sulfenylating agent. Malonate 103 and catalyst 10a, 
the optimized substrate and catalyst for asymmetric phase-transfer catalytic α-alkylation, 
only gave a low yield (~40%) and enantioselectivity (~10 % ee). The results suggeted that 
phthalimides as electophilde were concerned in forming the ion pair of substrate enolate 
with catalyst. 
 




2-2. Simplification and length variation of alkyl moiety at ester for 
observing changes in asymmetric alkylation of malonate 
We have researched the direct enantioseletive α-alkylation of malonate via phase-transfer 
catlysis very much.[72, 74, 90-91] We needed an in-depth study of the asymmetric phase-
transfer catalytic α-alkylation of malonate. As the beginning, we made a plan for the 
simplification and extension of alkyl moiety at ester in the other side of tert-butyl ester 
(Scheme 42). All planned malonates as below were synthesized directly from EDC 
coupling with commercial available alcohols. 
Scheme 42. Synthesis and test reaction of modified malonates 
First study was the simplification of benzylideneamino group (Figure 12). When we 
develop benzylideneamino tert-butyl malonates, we then thought a rigidity of substrate so 
introduced double bond instead of single bond to synthesize oxime ester malonate, not 
aminooxy malonate. But that speculation about rigidity needed verification. Therefore, 
we conducted the simplification converting oxime esters to ordinary alkyl esters. 
Diphenylmethylideneamino tert-butyl malonate (66), (E)-benzylideneamino tert-butyl 
malonate (92) and (E)-4-bromobenzylideneamino tert-butyl malonate (103) were selected 
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as representative substrates of benzylideneamino tert-butyl malonate. Nitrogen of oxime 
ester was converted to hydrocarbon and double bond to single bond. As a result, 
diphentylethyl tert-butyl malonate (111), phenylethyl tert-butyl malonate (112) and 4-
bromophenylethyl tert-butyl malonate (113) were synthesized as below. 
 
Figure 12. First study : simplification of benzylideneamino group 
Original malonate substrate and modified substrate were benzylated in the same condition, 
using benzyl bromide as a benzylating agent, catalyst 10a, 50% aqueous potassium 
hydroxide and toluene as solvent at 0°C (Scheme 43). Benzylated product 111a of 
diphentylethyl substrate, modified, rather showed a better yield and enantiomeric excess. 
Although the value was small, that seemed to demonstrate that our speculation about 
rigidity was wrong. However, product 112a of phenylethyl substrate gave a slightly 
decreased yield and enantiomeric excess and 113a, product of substrate modified from the 
best substrate 103 for asymmetric phase-transfer catalytic alkylation, presented a clearly 
decreased enantioselectivity. More studies were needed, but our speculation about rigidity 
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was thought not to be important in asymmetric phase-transfer catalystic alkylation of 
alkyl ester malonate containing non-substituted phenyl group. 
Scheme 43. Benzylation test of simplified malonate 
Second study began from phenylethyl tert-butyl malonate (112). In malonate 112, two 
hydrocarbon is located between oxygen of phenylethyl ester and phenyl group. We tried 
to control the number of hydrocarbon and observed the difference of the asymmetric 
alkylation depending on the number (Figure 13). Benzyl tert-butyl malonate (114) was 
synthesized as a reduced hydrocarbon malonate[91], phenyl n-propyl tert-butyl malonate 





Figure 13. Second study : length variation of alkyl chain on ester 
Length-modified malonate substrates were benzylated in the condition as above 
mentioned (Scheme 44). Asymmetric benzylation of benzyl tert-butyl malonate (114), 
one hydrocarbon substrate, presented product 114a with a lower enantiomeric excess than 
112a (81 → 71% ee).[91] Benzylated product 115a from phenyl n-propyl tert-butyl 
malonate (115) showed severe decrease in enantiomeric excess (81 → 45% ee). 116a, 
benzylated product of phenyl n-propyl tert-butyl malonate (116) also gave lower 
enantiomeric excess than it of 112a(56% ee). 112a presented the best result (88%, 81% 
ee). 
Scheme 44. Benzylation of length-modified malonate substrates 
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It implied that two carbon seemed to be proper between group interacting catalyst (e.g. 
phenyl group) and oxygen of ester. But the previous result 24a showed that the 
implication was not right (Scheme 45). Benzylated product 24a of diphenylmethyl tert-
butyl malonate (23d)[72], first developed malonate for asymmetric phase-transfer catalytic 
alkylation firstly, presented higher enantioselectivity than 111a, benzylated adduct of 
simplified malonate 111. Related follow-up research is in progress. 











A novel enantioselective phase-transfer catalytic α-alkylation of benzylideneamino tert-
butyl malonates has been developed. Asymmetric phase-transfer catalytic α-alkylation of 
(E)-4-bromobenzylideneamino tert-butyl α-methylmalonate afforded the corresponding 
α,α-dialkylmalonates in high chemical (up to 97%) and optical (up to 98% ee) yields. It is 
notable that the selective hydrolysis under basic and acidic conditions as well as catalytic 
hydrogenation extended the usefulness of the enantioselective phase-transfer catalytic α-
alkylation of the malonate system, which was confirmed by its application to the 
synthesis of chiral α-alkyl-α-carboxylactone. Our new catalytic system provided an 
attractive synthetic method for various chiral building blocks that could be readily 
converted en route to the synthesis of versatile chiral target molecules with the 
involvement of quaternary carbon centers. 
In addition, the enantioselective phase-transfer catalytic α-sulfenylation was achieved in 
high chemical (92%) and optical (90% ee) yields using benzhydrylideneamino tert-butyl 
malonate as a substrate. And the change of chiral induction in the asymmetric phase-
transfer catalytic alkylation of modified malonates was observed through simplification 
of representative benzylidene malonates and carbon length-varied malonates.  
These results contribute the asymmetric α-substitution of malonate as an attractive 
synthetic method for chiral fundamental unit molecules, which can be very useful in the 






1. General methods 
1-1. Solvents and reagents 
All reagents bought from commercial sources were used without further purification. 
Organic solvents were concentrated under reduced pressure using a Büchi rotary 
evaporator. As the commercially available KOH was a pellet type, solid KOH should be 
grinded to the powder form for successful reaction and high enantiopurity. 50% w/v 
aqueous NaOH, KOH, and CsOH were used as stock solutions. Phase-transfer catalyst 
10a, 10b was purchased from the commercial source (Wako). Phase-transfer catalysts (5b, 
5l, 5n, 5o, 8f) were prepared according to the reported procedures.[16, 22-23] 
 
1-2. Chromatography and HPLC 
TLC analyses were performed using Merck precoated TLC plate (silica gel 60 GF254, 0.25 
mm). Flash column chromatography was carried out using E. Merck Kieselgel 60 
(230~400 mesh). Instrument (Hitachi, L-2130) and software (Hitachi, Version LaChrom 
8908800-07) were used as HPLC analysis. The values of enantiomeric excess (ee) of 
chiral products were determined by HPLC using 4.6 mm ⅹ 250 mm Daicel Chiralcel 
OD-H, Chiralpak AD-H, Chiralpak AS-H, and Chiralcel OJ-H. 
 
1-3. Spectra data 
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Infrared (IR) spectra were recorded on a JASCO FT/IR-300E and Perkin-Elmer 1710 FT 
spectrometer. Nuclear magnetic resonance (1H-NMR and 13C-NMR) spectra were 
measured on JEOL JNM-LA 300 [300 MHz (1H), 600 MHz (13C)] spectrometer, JEOL 
JNM-GSX 400 [400 MHz (1H), 100 MHz (13C)] spectrometer, and Bruker AMX 500 [500 
MHz (1H), 125 MHz (13C)] spectrometer, using CHCl3-d as solvents, and were reported in 
ppm relative to CHCl3 (δ 7.24) for 1H-NMR and relative to the central CDCl3 (δ 7.23) 
resonance for 13C-NMR. Coupling constants (J) in 1H-NMR are in Hz. Low-resolution 
mass spectra (LRMS) and high-resolution mass spectra (HRMS) were measured on a 
JEOL JMS 700 or JEOL JMS 600-W spectrometer. Melting points were measured on a 
Büchi B-540 melting point apparatus and were not corrected. Optical rotations were 
measured on a JASCO polarimeter P-2000 series. 
 
2. Benzylideneamino tert-butyl malonate 
2-1. Synthesis of quinine-derived phase-transfer catalyst 5m 
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Hydroquinine (1000mg, 3.1mmol) was dissolved with stirred MC (10mL). 2,3,4-
Trifluorobenzyl bromide(0.441mL, 3.37mmol) was added to the reaction mixture. After 
heating for 20 h, the reaction mixture was evaporated. The residue was purified by 
column chromatography (silica gel 230~400mesh, MC : MeOH = 15:1 to 10:1) to afford 
quininium bromide (1658mg, 98%). The ammonium (1000mg, 1.8mmol) was added to 
stirred MC (10mL). To the reaction mixture were added 50% KOH (aq., 1mL, 9.1mmol) 
and allyl bromide (0.614mL, 7.3mmol). After stirring for 20 h, the reaction mixture was 
diluted with MC then washed with water. The organic extract was dried over MgSO4. The 
solvent was removed under reduced pressure, and the residue was purified by column 
chromatography (230~400mesh silica gel, MC : MeOH = 20:1 to 10:1) to give 5m 




Pink solid. 1H-NMR(300 MHz, DMSO) δ 8.82(d, J = 
4.38Hz, 1H), 8.02(d, J = 9.18Hz, 1H), 7.77(d, J = 4.56Hz, 
2H), 7.59(q, J = 8.43Hz, 1H), 7.49(dd, J1 = 9.17Hz, J2 = 
2.37Hz, 1H), 7.40(d, J = 2.22Hz, 1H), 6.77(d, J = 4.02Hz, 
1H), 6.58(d, J = 3.66Hz, 1H), 5.55(d, J = 12.81Hz, 1H), 
4.72(d, J = 12.81Hz, 1H), 4.26(t, J = 10.62Hz, 1H), 4.04(s, 3H), 4.00(t, J = 8.76Hz, 1H), 
3.44(d, J = 10.08Hz, 2H), 3.28~3.26(m, 1H), 2.24~2.14(m, 2H), 1.97(s, 1H), 
1.81~1.73(m, 2H), 1.45(t, J = 11.16Hz, 1H), 1.30(o, J = 7.14Hz, 2H), 0.73(t, J = 7.32Hz, 
3H) ; 13C-NMR(500 MHz, DMSO) δ 157.34, 152.67, 152.60, 151.80, 150.68, 150.61, 
149.79, 147.35, 143.75, 143.68, 140.42, 138.56, 138.44, 131.32, 130.21, 125.41, 121.46, 
120.31, 113.78, 11369, 113.44, 113.30, 102.23, 68.22, 63.73, 61.22, 56.36, 55.61, 54.92, 
50.92, 35.21, 25.15, 24.85, 23.62, 20.17, 11.21 ; ; IR(KBr) 3200, 2960, 1620, 1590, 1514, 
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1492, 1474, 1431, 1360, 1311, 1240, 1226, 1163, 1119, 1075, 1024, 957, 914, 859, 826, 
753, 719, 684, 661, 647 cm-1 ; HRMS(FAB) calcd for [C27H30BrF3N2O2]+ : 550.1443, 
found : 551.1521. [α]25D = -141.03 (c 1.0, CHCl3). 
 
(1S,2S,4S,5R)-2-((R)-(allyloxy)(6-methoxyquinolin-4-yl)methyl)-5-ethyl-1-(2,3,4-
trifluorobenzyl)quinuclidin-1-ium bromide (5m) 
Yellow solid. 1H-NMR(300 MHz, DMSO) δ 8.85(d, J = 
4.38Hz, 1H), 8.05(d, J = 8.05Hz, 1H), 7.65(d, J = 4.56Hz, 
2H), 7.60(d, J = 6.96Hz, 1H), 7.53(dd, J1 = 9.06Hz, J2 = 
2.10Hz, 1H), 7.34(s, 1H), 6.41(s, 1H), 6.14(o, J = 5.53Hz, 
1H), 5.47(d, J = 17.19Hz, 1H), 5.30(d, J = 10.44Hz, 1H), 
4.72(d, J = 13.74Hz, 1H), 4.29(dd, J = 6.57Hz, 1H), 
4.06~3.90(m, 3H), 3.98(s, 3H), 3.43~3.40(m, 2H), 3.30(m, 1H), 2.28(m, 1H), 2.09(m, 
1H), 1.99(s, 2H), 1.76(m, 2H), 1.52(m, 1H), 1.23~1.15(m, 3H), 0.72(t, J = 7.32Hz, 3H) ; 
13C-NMR(500 MHz, DMSO) δ 157.44, 152.75, 152.70, 151.82, 151.74, 150.74, 150.69, 
149.79, 149.72, 147.41, 144.05, 140.56, 140.44, 140.31, 139.66, 138.57, 138.45, 134.14, 
131.35, 130.37, 126.12, 121.81, 119.81, 117.29, 102.18, 71.89, 69.26, 67.87, 61.01, 59.71, 
56.68, 55.58, 51.02, 35.02, 25.01, 24.90, 23.61, 20.71, 20.20, 14.04, 11.16 ; IR(KBr) 
2929, 1736, 1619, 1588, 1513, 1492, 1475, 1458, 1432, 1372, 1309, 1240, 1161, 1131, 
1071, 1024, 939, 913, 860, 828, 753, 721, 684, 660, 649, 624 cm-1 ; HRMS(FAB) calcd 






2-2. General procedure for benzylideneamino tert-butyl malonate 
tert-Butanolysis of a-methylmeldrum’s acid
 
a-methylmeldrum’s acid (67, 2000mg, 12.6mmol) was added to stirred t-BuOH (30mL). 
After reflux for 12 h, the reaction mixture was evaporated to afford 68 (2190mg, 99% 
yield) as colorless oil. 1H-NMR(300 MHz, CDCl3) δ 11.5(s, 1H), 3.31(q, J = 7.26Hz, 1H), 
1.37(s, 9H), 1.32(d, J = 7.35Hz, 3H) ; 13C-NMR(400 MHz, CDCl3) δ 175.54, 169.19, 
82.06, 46.87, 27.75, 13.48 ; IR(KBr) 3104, 2982, 2943, 2726, 2639, 1732, 1716, 1458, 
1415, 1394, 1370, 1321, 1284, 1250, 1154, 1085, 1024, 927, 912, 840, 747, 672 cm-1 ; 
HRMS(FAB) : calcd for [C8H14O4]+ : 174.0892 , found : 175.0967 
 
2-2-1. Synthetic route for oxime 




Hydroxylamine hydrochloride (1754mg, 25.2mmol) and sodium acetate (2250mg, 
27.4mmol) were added to a solution of benzophenone (2000mg, 11.0mmol) in MeOH 
(40mL). After reflux for 24 h, excess water was poured. Formed solid was filtered and 
washed with water to afford ketoxime (99%) as white solid. 
 
Diphenylmethanone oxime (82) 
Following the general procedure (A-1) from benzophenone. White solid 
(mp : 125.4 oC). 1H-NMR(300 MHz, DMSO) δ 11.35(s, 1H), 
7.48~7.27(m, 10H) ; 13C-NMR(300 MHz, DMSO) δ 155.01, 136.71, 
133.47, 128.83, 128.76, 128.30, 128.25, 128.06, 126.91 ; IR(KBr) 3725, 3273, 3058, 
2349, 1494, 1444, 1330, 1162, 998, 934, 920, 785, 766, 697, 660 cm-1 ; HRMS(FAB) : 
calcd for [C13H11NO]+ : 197.0841 , found : 198.0921 
 
(E)-1-Phenylethan-1-one oxime (83) 
Following the general procedure (A-1) from acetophenone. Purified by 
column chromatography (silica gel, hexane : EtOAc = 5:1). White solid 
(mp : 59.7 oC). 1H-NMR(300 MHz, DMSO) δ 11.26(s, 1H), 7.66(d, J = 
3.71Hz, 2H), 7.35(d, J = 3.48Hz, 3H), 2.17(s, 3H) ; 13C-NMR(300 MHz, DMSO) δ 
152.95, 137.08, 128.57, 128.34, 125.58, 11.58 ; IR(KBr) 3253, 1497, 1447, 1371, 1303, 
1219, 1079, 1007, 927, 771, 694, 654 cm-1 ; HRMS(FAB) : calcd for [C8H9NO]+ : 





(A-2) General procedure for the preparation of aldoximes 
 
Hydroxylamine hydrochloride (989mg, 14.2mmol) and potassium carbonate (1966mg, 
14.2mmol) were added to a solution of benzaldehyde (1000mg, 7.1mmol) in EtOH 
(10mL). To the reaction mixture was added water (10mL). After stirred for 24 h, the 
mixture was diluted with ethyl acetate and washed with water. The organic extract was 
dried over MgSO4. The solvent was removed under reduced pressure, and the residue was 
purified by column chromatography (230~400mesh silica gel, hexane : EtOAc = 5 : 1) to 
give aldoxime (88%) as white solid.  
 
(E)-Benzaldehyde oxime (84) 
Following the general procedure (A-2) from benzaldehyde. White solid 
(mp : 31.8 oC ). 1H-NMR(300 MHz, DMSO) δ 11.31(s, 1H), 8.17(s, 1H), 
7.60(dd, J1 = 7.56Hz, J2 = 2.19Hz, 2H), 7.40~7.32(m, 3H) ; 13C-
NMR(300 MHz, DMSO) δ 148.34, 130.54, 129.61, 129.39, 128.83, 128.51 ; IR(KBr) 
3312, 3064, 3029, 2983, 2897, 1955, 1812, 1632, 1602, 1577, 1494, 1445, 1305, 1290, 
121, 1177, 158, 1085, 952, 871, 846, 755, 691, 645 cm-1 ; HRMS(FAB) : calcd for 
[C7H7NO]+ : 121.0528, found : 122.0607 
87 
 
(E)-1-naphthaldehyde oxime (85) 
Following the general procedure (A-2) from 1-naphthaldehyde. 
Yellow solid (mp : 98.2 oC). 1H-NMR(300 MHz, DMSO) δ 
11.55(s, 1H), 8.81(s, 1H), 8.68(d, J = 8.04Hz, 1H), 7.95~7.91(m, 
2H), 7.81(d, J = 7.14Hz, 1H), 7.60~7.49(m, 3H) ; 13C-NMR(300 
MHz, DMSO) δ 148.23, 133.44, 123.00, 129.63, 128.78, 128.57, 126.86, 126.10, 125.46, 
124.69 ; IR(KBr) 3318, 1511, 1220, 1171, 1038, 949, 886, 800, 772, 644 cm-1 ; 
HRMS(FAB) : calcd for [C11H9NO]+ : 171.0684, found : 172.0758 
 
(E)-2-naphthaldehyde oxime (86) 
Following the general procedure (A-2) from 2-naphthaldehyde. 
White solid (mp : 165.1 oC). 1H-NMR(300 MHz, DMSO) δ 
11.42(s, 1H), 8.31(s, 1H), 7.99(s, 1H), 7.96~7.82(m, 4H), 
7.57~7.49(m, 2H) ; 13C-NMR(300 MHz, DMSO) δ 148.22, 133.27, 130.78, 128.31, 
128.04, 127.68, 127.45, 126.65, 126.61, 122.48 ; IR(KBr) 2982, 1771, 1732, 1612, 1457, 
1369, 1338, 1220, 1145, 1076, 946, 864, 772 cm-1 ; HRMS(FAB) : calcd for [C11H9NO]+ : 
171.0684, found : 171.0687 
 
(E)-4-methoxybenzaldehyde oxime (87) 
Following the general procedure (A-2) from p-anisaldehyde. 
White solid (mp : 67.8 oC). 1H-NMR(300 MHz, DMSO) δ 
11.00(s, 1H), 8.08(s, 1H), 7.52(d, J = 8.79Hz, 2H), 6.93(d, J = 
8.76Hz, 2H), 3.74(s, 3H) ; 13C-NMR(300 MHz, DMSO) δ 160.13, 147.69, 127.87, 125.66, 
114.18, 55.15 ; IR(KBr) 3279, 3248, 3165, 3016, 2971, 2945, 2839, 2557, 2321, 2030, 
88 
 
1608, 1576, 1515, 1463, 1417, 1328, 1304, 1251, 1173, 1108, 108, 958, 873, 825, 807, 
772, 709, 636 cm-1 ; HRMS(FAB) : calcd for [C8H9NO2 ]+ : 151.0633 , found : 152.0712 
 
 
(E)-2-fluorobenzaldehyde oxime (88) 
Following the general procedure (A-2) from 2-Fluorobenzaldehyde. 
White solid (mp : 40.7 oC). 1H-NMR(300 MHz, CDCl3) δ 8.98(s, 1H), 
8.45(s, 1H), 7.80(td, J1 = 7.35Hz, J2 = 1.56Hz, 1H), 7.49~7.41(m, 1H), 
7.27~7.15(m, 2H) ; 13C-NMR(500 MHz, DMSO) δ 160.87, 158.89, 141.66, 131.18, 
126.79, 124, 74, 120.61, 116.05 ; IR(KBr) 3322, 2321, 1615, 1578, 1492, 1460, 1316, 
1296, 1237, 1183, 1183, 1153, 1101, 971, 900, 879, 808, 756, 630 cm-1 ; HRMS(FAB) : 
calcd for [C7H6FNO]+ : 139.0433 , found : 140.0508 
 
 
(E)-3-fluorobenzaldehyde oxime (89) 
Following the general procedure (A-2) from 3-Fluorobenzaldehyde. 
White solid (mp : 72.4 oC). 1H-NMR(300 MHz, CDCl3) δ 8.11(s, 
2H), 7.38~7.28(m , 3H), 7.10~7.04(m, 1H) ; 13C-NMR(500 MHz, 
DMSO) δ 163.36, 161.43, 147.26, 135.69, 130.75, 122.75, 116.08, 112.70 ; IR(KBr) 3265, 
3018, 1584, 1489, 1448, 1327, 1272, 1257, 1141, 969, 954, 861, 779, 679 cm-1 ; 
HRMS(FAB) : calcd for [C7H6FNO]+ : 139.0433 , found : 140.0507; HRMS(FAB) : calcd 




(E)-4-fluorobenzaldehyde oxime (90) 
Following the general procedure (A-2) from 4-Fluorobenzaldehyde. 
White solid (mp : 91.1 oC). 1H-NMR(300 MHz, CDCl3) δ 8.31(s, 
1H), 8.11(s, 1H), 7.58~7.52(m, 2H), 7.10~7.03(m, 2H) ; 13C-
NMR(500 MHz, DMSO) δ 163.64, 161.67, 147.10, 129.71, 128.50, 115.79 ; IR(KBr) 
3826, 3648, 3301, 2318, 1747, 1715, 1681, 1647, 1608, 1515, 1489, 1297, 974, 827, 650 
cm-1 ; HRMS(FAB) : calcd for [C7H6FNO]+ : 139.0433 , found : 140.0515 
 
(E)-4-chlorobenzaldehyde oxime (91) 
Following the general procedure (A-2) from 4-Chlorobenzaldehyde. 
White solid (mp : 110.8 oC). 1H-NMR(300 MHz, CDCl3) δ 8.09(s, 
1H), 8.00(s, 1H), 7.49(dt, J1 = 8.61Hz, J2 = 2.13Hz, 2H), 7.34(dt, J1 
= 8.61Hz, J2 = 2.19Hz, 2H) ; 13C-NMR(500 MHz, DMSO) δ 147.10, 133.71, 132.00, 
128.76, 128.01 ; IR(KBr) 3840, 3307, 2311, 1746, 1705, 1681, 1596, 1495, 1397, 1318, 
1089, 974, 955, 934, 876, 822, 692 cm-1 ; HRMS(FAB) : calcd for [C7H6ClNO]+ : 
155.0138 , found : 156.0214 
 
(E)-4-bromobenzaldehyde oxime (92) 
Following the general procedure (A-2) from 4-Bromobenzaldehyde. 
White solid (mp : 114.2 oC). 1H-NMR(300 MHz, CDCl3) δ 8.38(s, 
1H), 8.01(s, 1H), 7.51(dt, J1 = 8.61Hz, J2 = 2.01Hz, 2H), 7.42(dt, J1 
= 8.43Hz, J2 = 2.01Hz, 2H) : 13C-NMR(500 MHz, DMSO) δ 
147.20, 132.34, 131.67, 128.27, 122.39 ; IR(KBr) 3841, 3305, 2310, 1746, 1706, 1681, 







HRMS(FAB) : calcd for [C7H6BrNO]+ : 198.9633 , found : 199.9715 
 
(E)-4-iodobenzaldehyde oxime (93) 
Following the general procedure (A-2) from 4-Iodobenzaldehyde. 
White solid (mp : 120.1 oC). 1H-NMR(300 MHz, CDCl3) δ 7.99(s, 
1H), 7.85~7.82(m, 1H), 7.65(dt, J1 = 8.40Hz, J2 = 2.01Hz, 2H), 
7.23(dt, J1 = 8.43Hz, J2 = 1.92Hz, 2H) ; 13C-NMR(500 MHz, DMSO) δ 147.40, 137.50, 
132.62, 128.29, 95.63 ; IR(KBr) 3840, 3288, 2350, 1746, 1705, 1681, 1586, 1508, 1488, 
1393, 1311, 1055, 1004, 968, 950, 928, 868, 812, 682 cm-1 ; HRMS(FAB) : calcd for 













2-2-2. Synthetic route for benzylideneamino malonic ester 
(B) General procedure for phase-transfer catalytic substrates 
HO Ot-Bu
OO

























































EDC hydrochloride (660mg, 3.4mmol) and DMAP (21mg, 0.2mmol) were added to a 
solution of 68 (300mg, 1.7mmol) in dioxane (6mL). Oxime (1.7mmol) was added to the 
solution. After stirred for 24 h, the mixture was diluted with ethyl acetate and washed 
with water. The organic extract was dried over MgSO4. The solvent was removed under 
reduced pressure, and the residue was purified by column chromatography (230~400mesh 





tert-butyl 3-{[(diphenylmethylene)amino]oxy}-2-methyl-3-oxopropanoate (66) 
Following the general procedure (B). White solid (mp : 
83.5 oC). 1H-NMR(300 MHz, CDCl3) δ 7.59(d, J = 7.86Hz, 
2H), 7.48~7.42(m, 4H), 7.39~7.31(m, 4H), 3.42(q, J = 
7.32Hz, 1H), 1.37(s, 9H), 1.34(s, 3H) ; 13C-NMR(300 MHz, 
CDCl3) δ 168.41, 165.00, 134.48, 132.11, 130.94, 129.68, 
128.86, 128.12, 81.83, 46.15, 27.74, 13.45 ; IR(KBr) cm-1 2981, 1774, 1733, 1446, 1328, 
1159, 1076, 1031, 985, 917, 877, 848, 781, 697, 647 ; HRMS(FAB) : calcd for 
[C21H23NO4]+ : 353.1627 , found : 354.1703 
 
tert-butyl (E)-2-methyl-3-oxo-3-{[(1-phenylethylidene)amino]oxy}propanoate (94) 
Following the general procedure (B). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 7.75~7.71(m, 2H), 
7.46~7.33(m, 3H), 3.60(q, J = 7.32Hz, 1H), 2.37(s, 3H), 
1.47(d, J = 7.14Hz, 3H), 1.43(s, 9H) ; 13C-NMR(500 
MHz, CDCl3) δ 169.66, 169.03, 141.12, 128.44, 127.92, 126.08, 81.54, 73.01, 47.25, 
27.86, 21.97, 13.44 ; IR(KBr) cm-1 3448, 980, 2881, 2348, 1772, 1732, 1617, 1573, 1455, 
1370, 1319, 1157, 1072, 983, 904, 847, 787, 763, 694 ; HRMS(FAB) : calcd for 
[C16H21NO4]+ : 291.1471 , found : 292.1548 
 
tert-butyl (E)-3-((benzylideneamino)oxy)-2-methyl-3-oxopropanoate (95) 
Following the general procedure (B). White solid (mp : 
62.0 oC). 1H-NMR(300 MHz, CDCl3) δ 8.34(s, 1H), 











1H), 1.47(d, J = 7.32Hz, 3H), 1.40(s, 9H) ; 13C-NMR(600 MHz, CDCl3) δ 168.51, 168.32, 
156.14, 131.79, 129.82, 128.87, 128.39, 82.01, 46.12, 27.82, 13.50 ; IR(KBr) 2980, 2941, 
2348, 1773, 1732, 1614, 1575, 1455, 1394, 1370, 1330, 1255, 1213, 1162, 1076, 951, 912, 





Following the general procedure (B). White solid (mp : 
66.0 oC). 1H-NMR(300 MHz, CDCl3) δ 8.96(s, 1H), 
8.59(d, J = 8.61Hz , 1H), 7.93(dd, J1 = 8.25Hz, J2 = 
7.35Hz, 3H), 7.66~7.48(m, 3H), 3.61(q, J = 7.14Hz , 1H), 
1.52(d, J = 7.14Hz, 3H), 1.46(s, 9H) ; 13C-NMR(600 MHz, CDCl3) δ 168.60, 168.26, 
156.27, 133.73, 13.53, 130.72, 129.89, 128.84, 127.91, 126.51, 125.82, 125.08, 124.58, 
82.07, 46.93, 27.86, 13.59 ; IR(KBr) 2981, 2348, 1771, 1731, 1585, 1512, 1456, 1370, 
1338, 1229, 1161, 1078, 1023, 943, 911, 874, 803 cm-1 ; HRMS(FAB) : calcd for 




Following the general procedure (B). White solid (mp : 
114.7 oC). 1H-NMR(300 MHz, CDCl3) δ 8.49(s, 1H), 
8.03~7.83(m, 5H), 7.56~7.52(m, 2H), 3.58(q, J = 










13C-NMR(500 MHz, CDCl3) δ 168.55, 168.42, 156.21, 134.92, 132.84, 130.83, 128.87, 
128.58, 127.91, 127.88, 127.49, 126.86, 123.21, 82.05, 46.17, 27.85, 13.55 ; IR(KBr) 
2981, 2347, 1771, 1731, 1612, 1456, 1369, 1338, 1151, 1075, 1022, 966, 945, 911, 862, 
822, 750 cm-1 ; HRMS(FAB) : calcd for [C19H21NO4]+ : 327.1471, found : 327.1472 
 
tert-butyl (E)-3-{[(4-methoxybenzylidene)amino]oxy}-2-methyl-3-oxopropanoate (98) 
Following the general procedure (B). White solid (mp : 
69.2 oC). 1H-NMR(300 MHz, CDCl3) δ 8.28(s, 1H), 
7.65(d, J = 8.79Hz, 2H), 6.91(d, J = 8.79Hz, 2H), 3.8 
(s, 3H), 3.54(q, J = 7.32Hz, 1H), 1.46(d, J = 7.32Hz, 
3H), 1.44(s, 9H) ; 13C-NMR(600 MHz, CDCl3) δ 168.58, 168.46, 162.46, 155.69, 130.12, 
122.22, 114.33, 81.92, 55.34, 46.13, 27.81, 13.50 ; IR(KBr) 3565, 2980, 2310, 1770, 
1731, 1606, 1570, 1515, 1457, 1422, 1370, 1312, 1256, 1172, 1077, 1027, 948, 912, 835 
cm-1 ; HRMS(FAB) : calcd for [C16H21NO5]+ : 307.1420, found : 307.1417 
 
tert-butyl (E)-3-{[(2-fluorobenzylidene)amino]oxy}-2-methyl-3-oxopropanoate (99) 
Following the general procedure (B). White solid (mp : 
49.3 oC). 1H-NMR(300 MHz, CDCl3) δ 8.63(s, 1H), 
8.02~7.97(m, 1H), 7.49~7.42(m, 1H), 7.24~7.07(m, 2H), 
3.54(q, J = 7.32Hz, 1H), 1.47(d, J = 7.35Hz, 3H), 1.45(s, 
9H) ; 13C-NMR(600 MHz, CDCl3) δ 168.42, 168.10, 162.46, 160.77, 149.96, 133.65, 
127.73, 124.62, 117.87, 116.04, 82.10, 46.05, 27.85, 13.48 ; IR(KBr) +2981, 1349, 1778, 
1734, 1619, 1577, 1455, 1370, 1301, 1239, 1155, 1076, 957, 880, 762 cm-1 ; 










tert-butyl (E)-3-{[(3-fluorobenzylidene)amino]oxy}-2-methyl-3-oxopropanoate (100) 
Following the general procedure (B). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 8.31(s, 1H), 7.49~7.34(m, 
3H), 7.19~7.12(m, 1H), 3.56(q, J = 7.32Hz, 1H), 1.46(d, 
J = 7.32Hz, 3H), 1.43(s, 9H) ; 13C-NMR(600 MHz, 
CDCl3) δ 168.41, 168.10, 163.57, 161.73, 155.01, 131.95, 130.54, 124.54, 118.87, 114.63, 
82.09, 46.03, 27.80, 13.44 ; IR(KBr) 3446, 2981, 2310, 1775, 1613, 1582, 1451, 1370, 
1288, 1256, 1148, 1074, 979, 912, 847, 789, 685 cm-1 ; HRMS(FAB) : calcd for 
[C15H18FNO4]+ : 295.1220 , found : 296.1299 
 
tert-butyl (E)-3-{[(4-fluorobenzylidene)amino]oxy}-2-methyl-3-oxopropanoate (101) 
Following the general procedure (B). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 8.30(s, 1H), 7.73~7.68(m, 
2H), 7.12~7.05(m, 2H), 3.53(q, J = 7.32Hz, 1H), 1.45(d, 
J = 7.32Hz, 3H), 1.42(s, 9H) ; 13C-NMR(300 MHz, 
CDCl3) δ 170.19, 166.52, 163.16, 132.33, 130.48, 126.17, 119.35, 116.05, 81.93, 40.07, 
29.66, 19.76 ; IR(KBr) 3840, 3565, 2983, 2348, 2310, 1775, 1679, 1604, 1511, 1456, 
1370, 1338, 1232, 1158, 1012, 951, 840 cm-1 ; HRMS(FAB) : calcd for [C15H18FNO4]+ : 
295.1220 , found : 296.1290 
 
tert-butyl (E)-3-{[(4-chlorobenzylidene)amino]oxy}-2-methyl-3-oxopropanoate (102) 
Following the general procedure (B). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 8.31(s, 1H), 7.66(d, J = 
8.79Hz, 2H), 7.39(d, J = 8.58Hz, 2H), 3.53(q, J = 
96 
 
7.32Hz, 1H), 1.47(d, J = 7.32Hz, 3H), 1.44(s, 9H) ; 13C-NMR(300 MHz, CDCl3) δ 170.14, 
169.30, 155.03, 137.96, 132.24, 129.61, 129.26, 128.33, 119.44, 82.00, 40.67, 27.89, 
19.79 ; IR(KBr) 2981, 2310, 1775, 1732, 1596, 1491, 1456, 1370, 1212, 1162, 1089, 954, 
914, 828 cm-1 ; HRMS(FAB) : calcd for [C15H18ClNO4]+ : 311.0924, found : 312.1004 
 
tert-butyl (E)-3-{[(4-bromobenzylidene)amino]oxy}-2-methyl-3-oxopropanoate (103) 
Following the general procedure (B). White solid (mp : 
62.5 oC). 1H-NMR(300 MHz, CDCl3) δ 8.30(s, 1H), 
7.57(dd, J1 = 8.70Hz, J1 = 3.48Hz, 4H), 3.53(q, J = 
7.32Hz, 1H), 1.47(d, J = 7.32Hz, 3H), 1.44(s, 9H) ; 
13C-NMR(300 MHz, CDCl3) δ 170.17, 169.29, 155.19, 132.32, 129.79, 128.87, 126.45, 
119.40, 82.00, 40.10, 27.89, 19.80 ; IR(KBr) 3565, 2980, 2310, 1776, 1732, 1591, 1508, 
1488, 1456, 1397, 1370, 1338, 1162, 1071, 1010, 952, 914, 877, 822 cm-1 ; HRMS(FAB) : 
calcd for [C15H18BrNO4]+ : 355.0419 , found : 356.0498 
 
tert-butyl (E)-3-{[(4-iodobenzylidene)amino]oxy}-2-methyl-3-oxopropanoate (104) 
Following the general procedure (B). White solid (mp : 
98.6 oC). 1H-NMR(300 MHz, CDCl3) δ 8.27(s, 1H), 
7.77(d, J = 8.25Hz, 2H), 7.43(d, J = 8.4Hz, 2H), 3.52(q, 
J = 7.14Hz, 1H), 1.46(d, J = 7.14Hz, 3H), 1.44(s, 9H) ; 
13C-NMR(500 MHz, CDCl3) δ 168.41, 168.12, 155.26, 138.16, 129.68, 129.29, 98.66, 
82.10, 46.08, 27.83, 13.51 ; IR(KBr) 3902, 3840, 3734, 3647, 3565, 2348, 2310, 1777, 
1679, 1588, 1508, 1488, 1396, 1338, 1164, 1006 cm-1 ; HRMS(FAB) : calcd for 
[C15H18INO4]+ : 403.0281, found : 404.0360 
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2-3. General procedure of asymmetric phase-transfer catalytic α-
alkylation 
(C) General procedure for enantioselective phase-transfer catalytic α-alkylation 
 
Alkyl bromide (1.0 mmol) was added to a solution of PTC substrate (0.2mmol) and PTC 
catalyst (10a, 10b, 8f : 0.01mmol, 5b, 5l, 5m, 5n, 5o : 0.02mmol) in toluene (2.0mL). At 
the designated low temperature, base (1.0mmol) was added to the reaction mixture and 
stirred until the starting material disappeared. EYELA PSL -1400 was used for low 
temperature stirring and the stirring rate was 7. After completion of the reaction, the 
reaction mixture was diluted with ethyl acetate (10 ml), washed with brine (5 mL x 2), 
dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was 
purified by column chromatography(silica gel 230~400mesh, hexane : EtOAc = 20 : 1) to 





tert-butyl 2-{[((diphenylmethylene)amino)oxy]carbonyl}-2-methylpent-4-enoate (66b) 
Following the general procedure (C). White solid (mp : 
42.2 oC). 1H-NMR(300 MHz, CDCl3) δ 7.55(d, J = 7.14Hz, 
2H), 7.40~7.22(m, 8H), 5.64~5.50(m, 1H), 5.00(s, 1H), 
4.95(d, J = 8.43Hz, 1H), 2.42(h, J = 6.90Hz, 2H), 1.26(s, 
9H), 1.21(s, 3H) ; 13C-NMR(400 MHz, CDCl3) δ 169.99, 
169.16, 165.26, 134.44, 132.43, 132.28, 130.92, 129.61, 128.99, 128.64, 128.31, 128.11, 
119.01, 81.67, 53.50, 39.91, 27.66, 19.57 ; IR(KBr) 3748, 3063, 2979, 2933,1774, 1734, 
1593, 1491, 1446, 1369, 1324, 1253, 1147, 1090, 989, 697 cm-1 ; HRMS(FAB) : calcd for 
[C24H27NO4]+ : 393.1940, found : 394.2014. The enantioselectivity was determined by 
chiral HPLC analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 99 : 1, flow rate 




Following the general procedure (C). White solid (mp : 
59.3 oC). 1H-NMR(300 MHz, CDCl3) δ 7.74(dt, J1 = 
9.53Hz, J2 = 7.77Hz, 2H), 7.45~7.35(m, 3H), 
5.82~5.68(m, 1H), 5.12(d, J = 8.25Hz, 1H), 5.10(s, 1H), 
2.68(d, J = 7.32Hz, 2H), 2.34(s, 3H), 1.45(s, 3H), 1.43(s, 9H) ; 13C-NMR(500 MHz, 
CDCl3) δ 170.35, 169.20, 163.25, 134.49, 132.44, 130.67, 128.52, 127.02, 119.26, 81.57, 
53.68, 40.21, 27.84, 19.93, 14.23 ; IR(KBr) 3839, 3748, 3648, 2980, 2935, 1773, 1733, 
1641, 1541, 1456, 1370, 1253, 1146, 1100, 908, 693 cm-1 ; HRMS(FAB) : calcd for 
[C19H25NO4]+ : 331.1784, found : 332.1858. The enantioselectivity was determined by 
chiral HPLC analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 99 : 1, flow rate 
99 
 
= 1.0 mL/min, 23 oC, λ = 256 nm, retention times; minor 7.6 min, major 8.8 min, 63% ee. 
 
tert-butyl (E)-2-{[(benzylideneamino)oxy]carbonyl}-2-methylpent-4-enoate (95b) 
Following the general procedure (C). White solid (mp : 
56.0 oC). 1H-NMR(300 MHz, CDCl3) δ 8.31(s, 1H), 
7.72(d, J = 6.42Hz, 2H), 7.49~7.38(m, 3H), 5.81~5.67(m, 
1H), 5.15(d, J = 8.61Hz, 1H), 5.10(s, 1H), 2.67(d, J = 
7.35Hz, 2H), 1.44(s, 3H), 1.43(s, 9H) ; 13C-NMR(500 MHz, CDCl3) δ 170.22, 169.40, 
156.24, 132.34, 131.80, 129.84, 128.87, 128.44, 119.33, 81.89, 53.36, 40.05, 27.84, 
19.75 ; IR(KBr) 3862, 3748, 1078, 2980, 1774, 1734, 1641, 1613, 1575, 1508, 1450, 
1370, 1253, 1209, 1146, 1089, 995, 917, 846, 757, 693 cm-1 ; HRMS(FAB) : calcd for 
[C18H23NO4]+ : 317.1627 , found : 318.1706. The enantioselectivity was determined by 
chiral HPLC analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 99 : 1, flow rate 




Following the general procedure (C). White solid (mp : 
78.2 oC). 1H-NMR(300 MHz, CDCl3) δ 8.92(s, 1H), 
8.62(d, J = 8.61Hz, 1H), 7.96(d, J = 8.22Hz, 1H), 
7.89(d, J = 7.32Hz, 2H), 7.68~7.45(m, 3H), 
5.86~5.72(m, 1H), 5.20(s, 1H), 5.16~5.13(m, 1H), 2.72(d, J = 7.32Hz, 2H), 1.50(s, 3H), 
1.47(s, 9H) ; 13C-NMR(500 MHz, CDCl3) δ 170.33, 169.40, 156.34, 133.76, 132.56, 
132.42, 130.74, 129.98, 128.85, 127.97, 126.54, 125.89, 125.11, 124.68, 119.38, 81.96, 
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53.42, 40.12, 27.79, 19.80 ; IR(KBr) 3862, 3798, 3748, 3647, 3564, 2980, 2349, 1772, 
1736, 1611, 1508, 1456, 1369, 1253, 1146, 1088, 917, 748 cm-1 ; HRMS(FAB) : calcd for 
[C22H25NO4]+ : 367.1784, found : 368.1864. The enantioselectivity was determined by 
chiral HPLC analysis (DAICEL Chiralcel OD-H, hexane : 2-propanol = 99 : 1, flow rate 





Following the general procedure (C). White solid 
(mp : 78.9 oC). 1H-NMR(300 MHz, CDCl3) δ 8.47(s, 
1H), 8.03(s, 1H), 7.97(d, J = 8.61Hz, 1H), 
7.87~7.83(m, 3H), 7.58~7.49(m, 2H), 5.83~5.67(m, 
1H), 5.18(s, 1H), 5.13(d, J = 9.15Hz, 1H), 2.70(d, J = 7.32Hz, 2H), 1.47(s, 3H), 
1.45(s,9H) ; 13C-NMR(500 MHz, CDCl3) δ 170.24, 169.47, 156.32, 134.93, 132.84, 
132.36, 130.80, 128.85, 127.91, 127.86, 127.51, 126.85, 123.32, 119.36, 81.92, 53.40, 
40.09, 27.86, 19.79 ; IR(KBr) 3748, 3647, 2980, 2935, 2349, 1772, 1733, 1612, 1456, 
1369, 1253, 1146, 1089, 917, 749 cm-1 ; HRMS(FAB) : calcd for [C22H25NO4]+ : 
367.1784, found : 368.1861. The enantioselectivity was determined by chiral HPLC 
analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 99 : 1, flow rate = 1.0 mL/min, 






Following the general procedure (C). Colorless oil. 
1H-NMR(300 MHz, CDCl3) δ 8.25(s, 1H), 7.66(d, J 
= 8.79Hz, 2H), 6.91(d, J = 8.79Hz, 2H), 
5.81~5.67(m, 1H), 5.14(d, J = 8.43Hz, 1H), 5.10(s, 
1H), 3.83(s, 3H), 2.66(d, J = 7.35Hz, 2H), 1.43(s, 12H) ; 13C-NMR(600 MHz, CDCl3) δ 
170.27, 169.54, 162.46, 155.79, 132.41, 130.16, 122.25, 119.24, 114.33, 81.80, 55.35, 
53.34, 40.06, 27.83, 19.75 ; IR(KBr) 3078, 2978, 2854, 2349, 1769, 1733, 1606, 1514, 
1458, 1421, 1369, 1304, 1256, 1171, 1146, 1091, 835 cm-1 ; HRMS(FAB) : calcd for 
[C19H25NO5]+ : 347.1733, found : 348.1816. The enantioselectivity was determined by 
chiral HPLC analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 90 : 10, flow rate 





Following the general procedure (C). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 8.60(s, 1H), 8.02(t, J = 6.69Hz, 
1H), 7.49~7.42(m, 1H), 7.15(dt, J1 = 25.14Hz, J2 = 8.42Hz, 
2H), 5.81~5.67(m,1H), 5.15(d, J = 8.43Hz, 1H), 5.11(s, 
1H), 2.67(d, J = 7.32Hz, 2H), 1.44(s, 3H), 1.44(s, 9H) ; 13C-NMR(600 MHz, CDCl3) δ 
170.13, 169.28, 162.45, 160.77, 150.02, 133.65, 132.29, 127.79, 124.63, 119.38, 117.84, 
115.89, 81.98, 53.40, 40.05, 27.84 ,19.75 ; IR(KBr) 379, 2980, 2348, 1778, 1735, 1618, 
1574, 1455, 1344, 1239, 1147, 1086, 919, 761 cm-1 ; HRMS(FAB) : calcd for 
[C18H22FNO4]+ : 335.1533, found : 336.1606. The enantioselectivity was determined by 
chiral HPLC analysis (DAICEL Chiralcel OD-H, hexane : 2-propanol = 95 : 5, flow rate 





Following the general procedure (C). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 8.29(s, 1H), 7.51~7.36(m, 
3H), 7.20~7.14(m, 1H), 5.80~5.67(m,1H), 5.15(d, J = 
7.32Hz, 1H), 5.11(s, 1H), 2.66(d, J = 7.32Hz, 2H), 
1.44(s, 3H), 1.43(s, 9H) ; 13C-NMR(600 MHz, CDCl3) δ 170.11, 169.18, 163.62, 161.98, 
155.10 ,132.25, 131.97, 124.55, 119.39, 118.90, 114.76, 81.97, 53.38, 40.04, 27.83, 
19.73 ; IR(KBr) 3724, 2981, 2348, 1776, 1735, 1582, 1451, 1370, 1255, 1147, 1089, 920, 
847, 790, 685, 649 cm-1 ; HRMS(FAB) : calcd for [C18H22FNO4]+ : 335.1533, found : 
336.1611. The enantioselectivity was determined by chiral HPLC analysis (DAICEL 
Chiralcel OD-H, hexane : 2-propanol = 95 : 5, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, 




Following the general procedure (C). White solid (mp : 
39.1 oC). Colorless oil. 1H-NMR(300 MHz, CDCl3) δ 
8.28(s, 1H), 7.56~7.70(m, 2H), 7.09(t, J = 8.70Hz, 2H), 
5.80~5.66(m,1H), 5.14(d, J = 7.68Hz, 1H), 5.09(s, 1H), 
2.65(d, J = 7.50Hz, 2H), 1.43(s, 12H) ; 13C-NMR(600 MHz, CDCl3) δ 170.14, 169.32, 
165.63, 163.95, 155.00, 132.28, 130.54, 126.10, 119.33, 116.23, 81.89, 53.35, 40.03, 
27.81, 19.72 ; IR(KBr) 3724, 3079, 2981, 2348, 1772, 1735, 1603, 1511, 1415, 1370, 
1232, 1158, 1089, 920, 841, 649 cm-1 ; HRMS(FAB) : calcd for [C18H22FNO4]+ : 











analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 90 : 10, flow rate = 1.0 




Following the general procedure (C). White solid (mp : 
49.6 oC). 1H-NMR(300 MHz, CDCl3) δ 8.28(s, 1H), 
7.67(d, J = 8.76Hz ,2H), 7.40(d, J = 8.40Hz, 2H), 
5.80~5.66(m,1H), 5.15(d, J = 7.53Hz, 1H), 5.10(s, 1H), 
2.66(d, J = 7.32Hz, 2H), 1.43(s, 12H) ; 13C-NMR(500 MHz, CDCl3) δ 170.14, 169.29, 
155.04, 137.95, 132.26, 129.60, 129.25, 128.36, 119.40, 81.96, 53.38, 40.05, 27.84, 
19.75 ; IR(KBr) 3724, 2980, 2348, 1776, 1735, 1596, 1491, 1370, 1253, 1148, 1089, 919, 
846 cm-1 ; HRMS(FAB) : calcd for [C18H22ClNO4]+ : 351.1237, found : 352.1320. The 
enantioselectivity was determined by chiral HPLC analysis (DAICEL Chiralpak AS-H, 
hexane : 2-propanol = 95 : 5, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; 




Following the general procedure (C). White solid (mp : 
70.5 oC). 1H-NMR(300 MHz, CDCl3) δ 8.30(s, 1H), 
7.58(q, J = 8.61Hz, 4H), 5.80~5.66(m,1H), 5.15(d, J = 
7.89Hz, 1H), 5.10(s, 1H), 2.66(d, J = 7.32Hz, 2H), 
1.43(s, 12H) ; 13C-NMR(600 MHz, CDCl3) δ 170.11, 
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169.24, 155.14, 132.42, 129.74, 129.01, 126.37, 119.38, 81.95, 53.50, 40.03, 27.83, 
19.73 ; IR(KBr) 2926, 2855, 2348, 2310, 175, 1735, 1641, 1614, 1590, 1488, 1456, 1369, 
1253, 1146, 1070, 918, 846, 648 cm-1 , HRMS(FAB) : calcd for [C18H22BrNO4]+ : 
395.0732, found : 396.0807. The enantioselectivity was determined by chiral HPLC 
analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 95 : 5, flow rate = 1.0 mL/min, 





Following the general procedure (C). White solid (mp : 
70.9 oC). 1H-NMR(300 MHz, CDCl3) δ 8.20(s, 1H), 
7.72(d, J = 8.22Hz ,2H), 7.40(d, J = 8.07Hz, 2H), 
5.75~5.61(m,1H), 5.10(d, J = 7.89Hz, 1H), 5.05(s, 1H), 
2.61(d, J = 7.14Hz, 2H), 1.38(s, 12H) ; 13C-NMR(600 
MHz, CDCl3) δ 170.10, 169.23, 155.34, 138.15, 132.25, 129.71, 119.39, 98.63, 81.95, 
53.37, 40.03, 27.84, 19.74 ; IR(KBr) 3724, 1565, 2979, 1934, 2348, 1734, 1588, 1456, 
1369, 1254, 1146, 1088, 919, 846 cm-1 ; HRMS(FAB) : calcd for [C18H22INO4]+ : 
443.0594 , found : 444.0670. The enantioselectivity was determined by chiral HPLC 
analysis (DAICEL Chiralcel OJ-H, hexane : 2-propanol = 90 : 10, flow rate = 1.0 mL/min, 






Following the general procedure (C). White solid (mp : 
83 - 85 oC). 1H-NMR(300 MHz, CDCl3) δ 8.23(s, 1H), 
7.59(q, J = 7.75Hz, 4H), 7.25~7.15(m, 5H), 3.26(q, J = 
12.63Hz, 2H), 1.44(s, 9H), 1.38(s, 3H) ; 13C-NMR(600 
MHz, CDCl3) δ 170.19, 169.17, 155.22, 135.93, 132.19, 
130.31, 129.76, 128.78, 128.16, 126.89, 126.40, 82.12, 
54.82, 41.03, 27.82, 19.88 ; IR(KBr) 3839, 2980, 1776, 1734, 1590, 1488, 1455, 1369, 
1253, 1151, 1113, 1083, 1011, 925, 847, 821, 735, 701 cm-1 ; HRMS(FAB) : calcd for 
[C22H24BrNO4]+ : 445.0889, found : 446.0952. The enantioselectivity was determined by 
chiral HPLC analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 90 : 10, flow rate 
= 1.0 mL/min, 23 oC, λ = 256 nm, retention times; S isomer (minor) 11.1 min, R isomer 
(major) 12.1 min, 97% ee. []  = +60.70 (c 1.0, CHCl3). 
 
tert-butyl (R,E)-2-{[((4-bromobenzylidene)amino)oxy]carbonyl}-2-methylpent-4-
enoate (103b)  
Following the general procedure (C). White solid (mp : 
70.5 oC). 1H-NMR(300 MHz, CDCl3) δ 8.30(s, 1H), 
7.58(q, J = 8.61Hz, 4H), 5.80~5.66(m, 1H), 5.15(d, J 
= 7.89Hz, 1H), 5.10(s, 1H), 2.66(d, J = 7.32Hz, 2H), 
1.43(s, 12H) : 13C-NMR(600 MHz, CDCl3) δ 170.11, 
169.24, 155.14, 132.42, 129.74, 129.01, 126.37, 119.38, 81.95, 53.50, 40.03, 27.83, 
19.73 ; IR(KBr) 2926, 2855, 2348, 2310, 175, 1735, 1641, 1614, 1590, 1488, 1456, 1369, 
1253, 1146, 1070, 918, 846, 648 cm-1 , HRMS(FAB) : calcd for [C18H22BrNO4]+ : 
395.0732, found : 396.0807. The enantioselectivity was determined by chiral HPLC 
analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 95 : 5, flow rate = 1.0 mL/min, 
23 oC, λ = 256 nm, retention times; S isomer (minor) 7.3 min, R isomer (major) 8.4 min, 
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90% ee. []  = +14.92 (c 1.0, CHCl3). 
tert-butyl (R,E)-2-{[((4-bromobenzylidene)amino)oxy]carbonyl}-2,4-dimethylpent-4-
enoate (103c) 
Following the general procedure (C). White solid (mp : 
72.1 oC). 1H-NMR(300 MHz, CDCl3) δ 8.29(s, 1H), 
7.60(q, J = 8.61Hz , 4H), 4.83(d, J = 32.61Hz, 2H), 
2.74(d, J = 3.30Hz, 2H), 1.72(s, 3H), 1.46(s, 3H), 
1.45(s, 9H) ; 13C-NMR(500 MHz, CDCl3) δ 170.62, 
169.59, 155.11, 140.54, 132.23, 129.79, 128.83, 126.42, 115.84, 82.05, 53.20, 42.93, 
27.82, 23.56, 19.89 ; IR(KBr) 2979, 2936, 1776, 1734, 1645, 1614, 1591, 1488, 1456, 
1396, 1369, 1302, 1251, 1155, 1115, 1072, 1036, 1011, 922, 896, 846, 821 cm-1 ; 
HRMS(FAB) : calcd for [C19H24BrNO4]+ : 409.0889, found : 410.0967. The 
enantioselectivity was determined by chiral HPLC analysis (DAICEL Chiralpak AD-H, 
hexane : 2-propanol = 99.5 : 0.5, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention 





Following the general procedure (C). White solid (mp : 
oC). 1H-NMR(300 MHz, CDCl3) δ 8.31(s, 1H), 7.59(q, 
J = 8.12Hz , 4H), 3.20(d, J = 13.00Hz, 2H), 2.74(d, J 
= 3.30Hz, 2H), 1.56(s, 3H), 1.45(s, 9H)  ; 13C-
NMR(500 MHz, CDCl3) δ 169.51, 168.57, 155.40, 
132.23, 129.81, 128.70, 127.21, 126.49, 121.86, 82.58, 53.34, 45.81, 27.79, 19.39 ; 
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IR(KBr) 2968, 1776, 1734, 1645, 1614, 1591, 1488, 1456, 1396, 1369, 1302, 1251, 1155, 
1115, 1072, 1036, 1011, 922, 896, 846, 821 cm-1 ; HRMS(FAB) : calcd for 
[C18H21Br2NO4]+ : 472.9837, found : 473.9923. The enantioselectivity was determined by 
chiral HPLC analysis (DAICEL Chiralcel OD-H, hexane : 2-propanol = 99 : 1, flow rate 
= 1.0 mL/min, 23 oC, λ = 256 nm, retention times; S isomer (minor) 15.9 min, R isomer 




Following the general procedure (C). White solid (mp : 
73 - 74 oC). 1H-NMR(300 MHz, CDCl3) δ 8.30(s, 1H), 
7.58(q, J = 6.47Hz, 4H), 7.39~7.18(m, 5H), 6.48(d, J 
= 15.75Hz, 4H), 6.19~6.12(m, 1H), 2.83(d, J = 
7.32Hz, 4H), 1.51(s, 3H), 1.46(s, 9H) ; 13C-NMR(600 
MHz, CDCl3) δ 170.09, 169.29, 155.26, 136.98, 134.19, 132.17, 129.73, 128.74, 128.45, 
127.34, 126.39, 126.24, 126.16, 123.96, 82.02, 53.91, 39.41, 27.84, 20.06 ; IR(KBr) 2979, 
1773, 1732, 1570, 1488, 1455, 1397, 1369, 1252, 1201, 1156, 1117, 1087, 1071, 1011, 
968, 927, 845, 743, 693 cm-1 ; HRMS(FAB) : calcd for [C24H26BrNO4]+ : 471.1045, 
found : 472.1114. The enantioselectivity was determined by chiral HPLC analysis 
(DAICEL Chiralpak AS-H, hexane : 2-propanol = 95 : 5, flow rate = 1.0 mL/min, 23 oC, λ 
= 256 nm, retention times; S isomer (minor) 12.4 min, R isomer (major) 10.4 min, 95% 






Following the general procedure (C). White solid (mp : 
70 - 71 oC). 1H-NMR(300 MHz, CDCl3) δ 8.29(s, 1H), 
7.58(q, J = 7.51Hz, 4H), 2.83(d, J = 1.83Hz, 2H), 
2.03(t, J = 2.66Hz, 1H), 1.59(s, 3H), 1.44(s, 9H) ; 13C-
NMR(600 MHz, CDCl3) δ 169.00, 168.27, 155.49, 
132.24, 129.79, 128.66, 126.52, 82.49, 78.86, 71.57, 53.06, 27.85, 25.87, 19.74 ; IR(KBr) 
3302, 2980, 1775, 1737, 1615, 1590, 1562, 1488, 1425, 1397, 1370, 1286, 1209, 1156, 
1086, 1011, 968, 918, 843, 735, 648 cm-1 ; HRMS(FAB) : calcd for [C18H20BrNO4]+ : 
393.0576, found : 394.0651. The enantioselectivity was determined by chiral HPLC 
analysis (DAICEL Chiralpak AS-H, hexane : 2-propanol = 90 : 10, flow rate = 1.0 
mL/min, 23 oC, λ = 256 nm, retention times; S isomer (minor) 7.9 min, R isomer (major) 




Following the general procedure (C). White solid 
(mp : 90 - 93 oC). 1H-NMR(300 MHz, CDCl3) δ 
8.24(s, 1H), 7.59(q, J = 7.88Hz, 4H), 7.05(s, 4H), 
3.22(q, J = 13.00Hz, 2H), 1.44(s, 9H), 1.37(s, 3H) ; 
13C-NMR(600 MHz, CDCl3) δ 170.28, 169.23, 
155.16, 136.43, 132.74, 132.19, 130.15, 129.76, 
128.87, 128.82, 126.38, 82.06, 54.83, 40.59, 27.84, 20.98, 19.81 ; IR(KBr) 2978, 2935, 
1775, 1734, 1614, 1590, 1561, 1514, 1487, 1457, 1397, 1369, 1340, 1300, 1273, 1252, 
1152, 1106, 1070, 1011, 959, 924, 890, 861, 844, 820, 787, 709 cm-1 ; HRMS(FAB) : 
calcd for [C23H26BrNO4]+ : 459.1045, found : 460.1123. The enantioselectivity was 
determined by chiral HPLC analysis (DAICEL Chiralpak AD-H, hexane : 2-propanol = 
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90 : 10, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; S isomer (minor) 





Following the general procedure (C). White solid. 1H-
NMR(300 MHz, CDCl3) δ 8.26(s, 1H), 7.61(q, J = 
6.16Hz, 4H), 7.18(t, J = 7.88Hz, 1H), 6.76(t, J = 
6.77Hz, 3H), 3.76(s, 3H), 3.26(q, J = 13.00Hz, 2H), 
1.47(s, 9H), 1.41(s, 3H) ; 13C-NMR(500 MHz, CDCl3) 
δ 170.26, 169.21, 159.38, 155.29, 137.49, 132.25, 
129.79, 129.15, 128.81, 126.46, 122.73, 116.16, 112.28, 82.20, 55.11, 54.82, 41.09, 27.87, 
19.92 ; IR(KBr) 3840, 3735, 2978, 2937, 2359, 1775, 1734, 1591, 1488, 1456, 1396, 
1369, 1263, 1154, 1112, 1070, 1011, 844, 700 cm-1 ; HRMS(FAB) : calcd for 
[C23H26BrNO5]+ : 475.0994, found : 477.0977 ;  The enantioselectivity was determined 
by chiral HPLC analysis (DAICEL Chiralcel OJ-H, hexane : 2-propanol = 90 : 10, flow 
rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; S isomer (minor) 16.0 min, R 







Following the general procedure (C). White solid (mp : 
85 - 86 oC). 1H-NMR(300 MHz, CDCl3) δ 8.23(s,1H), 
7.59(q, J = 7.32Hz, 4H), 7.14(dd, J1 = 8.67Hz, J2 = 
5.40Hz, 2H), 6.93(t, J = 8.69Hz, 2H), 3.23(q, J = 
12.26Hz, 2H), 1.43(s, 9H), 1.37(s, 3H) ; 13C-NMR(500 
MHz, CDCl3) δ 170.34, 169.35, 163.19, 161.24, 
155.55, 132.49, 132.10, 132.04, 131.90, 130.04, 128.96, 126.76, 115.36, 115.19, 82.54, 
55.06, 40.51, 28.09, 20.13 ; IR(KBr) 2979, 2937, 1774, 1734, 1605, 1590, 1563, 1509, 
1488, 1458, 1396, 1369, 1339, 1276, 1252, 1223, 1195, 1159, 1096, 1070, 1011, 959, 924, 
891, 862, 843, 823, 795, 726 cm-1 ; HRMS(FAB) : calcd for [C22H23Br2NO4]+ : 522.9994, 
found : 524.0068. The enantioselectivity was determined by chiral HPLC analysis 
(DAICEL Chiralpak OD-H, hexane : 2-propanol = 99 : 1, flow rate = 1.0 mL/min, 23 oC, 
λ = 256 nm, retention times; S isomer (minor) 15.5 min, R isomer (major) 16.5 min, 97% 




Following the general procedure (C). White solid (mp : 
87 - 88 oC). 1H-NMR(300 MHz, CDCl3) δ 8.23(s,1H), 
7.59(q, J = 7.32Hz, 4H), 7.14(dd, J1 = 8.67Hz, J2 = 
5.40Hz, 2H), 6.93(t, J = 8.69Hz, 2H), 3.23(q, J = 
12.26Hz, 2H), 1.43(s, 9H), 1.37(s, 3H) ; 13C-NMR(500 
MHz, CDCl3) δ 170.34, 169.35, 163.19, 161.24, 
155.55, 132.49, 132.10, 132.04, 131.90, 130.04, 128.96, 126.76, 115.36, 115.19, 82.54, 
55.06, 40.51, 28.09, 20.13 ; IR(KBr) 2979, 2937, 1774, 1734, 1605, 1590, 1563, 1509, 
1488, 1458, 1396, 1369, 1339, 1276, 1252, 1223, 1195, 1159, 1096, 1070, 1011, 959, 924, 
111 
 
891, 862, 843, 823, 795, 726 cm-1 ; HRMS(FAB) : calcd for [C22H23Br2NO4]+ : 522.9994, 
found : 524.0068. The enantioselectivity was determined by chiral HPLC analysis 
(DAICEL Chiralpak OD-H, hexane : 2-propanol = 99 : 1, flow rate = 1.0 mL/min, 23 oC, 
λ = 256 nm, retention times; S isomer (minor) 15.5 min, R isomer (major) 16.5 min, 97% 




Following the general procedure (C). White solid (mp : 
89 - 91 oC). 1H-NMR(300 MHz, CDCl3) δ 8.21(s, 1H), 
7.59(q, J = 7.20Hz, 4H), 7.37(d, J = 8.22Hz, 2H), 
7.05(d, J = 8.25Hz, 2H), 3.21(q, J = 13.43Hz, 2H), 
1.43(s, 9H), 1.37(s, 3H) ; 13C-NMR(600 MHz, CDCl3) 
δ 169.96, 168.97, 155.36, 135.00, 132.23, 132.05, 
131.28, 129.78, 128.66, 126.50, 121.01, 82.35, 54.68, 40.48, 27.82, 19.90 ; IR(KBr) 3829, 
2979, 1775, 1732, 1590, 1488, 1457, 1369, 1152, 1070, 1011, 924, 891, 845, 709 cm-1 ; 
HRMS(FAB) : calcd for [C22H23Br2NO4]+ : 522.9994, found : 524.0068. The 
enantioselectivity was determined by chiral HPLC analysis (DAICEL Chiralpak OJ-H, 
hexane : 2-propanol = 95 : 5, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; 







Following the general procedure (C). White solid (mp : 
96 - 98 oC). 1H-NMR(300 MHz, CDCl3) δ 8.20(s, 1H), 
7.62~7.56(m, 6H), 6.92(d, J = 8.25Hz, 2H), 3.19(q, J = 
13.91Hz, 2H), 1.43(s, 9H), 1.37(s, 3H) ; 13C-NMR(600 
MHz, CDCl3) δ 169.95, 168.94, 155.36, 137.25, 135.66, 
132.33, 129.79, 128.66, 126.49, 92.51, 82.34, 54.66, 
40.58, 27.82, 19.90 ; IR(KBr) 2978, 2935, 1774,1733, 1614, 1590, 1485, 1457, 1400, 
1369, 1267, 1152, 1114, 1100, 1070, 1009, 960, 924, 891, 846, 820, 709 cm-1 ; 
HRMS(FAB) : calcd for [C22H23BrINO4]+ : 570.9855 , found : 571.9924. The 
enantioselectivity was determined by chiral HPLC analysis (DAICEL Chiralpak OD-H, 
hexane : 2-propanol = 95 : 5, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; 





Following the general procedure (C). White solid (mp : 
95-98 oC). 1H-NMR(300 MHz, CDCl3) δ 8.22(s, 1H), 
7.83(q, J = 8.04Hz, 1H), 7.57(q, J = 7.20Hz, 4H), 
7.50~7.34(m, 3H), 3.71(q, J = 11.11Hz, 2H), 1.40(s, 
9H), 1.38(s, 3H) ; 13C-NMR(500 MHz, CDCl3) δ 
169.67, 168.77, 155.45, 150.73, 133.13, 132.46, 132.24, 
131.13, 129.81, 128.66, 128.03, 126.52, 124.75, 82.58, 55.03, 35.75, 27.73, 19.98 ; 
IR(KBr) 2979, 2933, 1774, 1734, 1612, 1590, 1528, 1487, 1457, 1397, 1369, 1352, 1301, 
1273, 1158, 1114, 1085, 1070, 1011, 925, 890, 844, 822, 787, 733, 709, 665 cm-1 ; 












enantioselectivity was determined by chiral HPLC analysis (DAICEL Chiralpak AD-H, 
hexane : 2-propanol = 90 : 10, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; 





Following the general procedure (C). White solid (mp : 
122 - 126 oC). 1H-NMR(300 MHz, CDCl3) δ 8.17(s, 
1H), 7.80~7.72(m, 3H), 7.64(s, 1H), 7.57(s, 4H), 
7.42(dd, J1 = 6.21Hz, J2 = 3.30Hz, 2H), 7.31(d, J = 
8.41Hz, 1H), 3.44(q, J = 11.35Hz, 2H), 1.45(s, 9H), 
1.43(s, 3H) ; 13C-NMR(500 MHz, CDCl3) δ 170.21, 
169.29, 155.37, 133.61, 132.24, 132.41, 132.20, 129.78, 129.15, 128.75, 128.52, 127.70, 
127062, 127.53, 126.44, 125.96, 125.62, 82.24, 55.04, 41.24, 27.87, 20.06 ; IR(KBr) 
3054, 2978, 2934, 1774, 1732, 1614, 1590, 1509, 1487, 1457, 1395, 1369, 1254, 1151, 
1070, 1011, 963, 902, 879, 845, 796, 751 cm-1 ; HRMS(FAB) : calcd for [C26H26BrNO4]+ : 
495.1045, found : 495.1042. The enantioselectivity was determined by chiral HPLC 
analysis (DAICEL Chiralpak OD-H, hexane : 2-propanol = 90 : 10, flow rate = 1.0 
mL/min, 23 oC, λ = 256 nm, retention times; S isomer (minor) 8.9 min, R isomer (major) 






Following the general procedure (C) at 0 °C for 24 h 
with aq. 50% KOH (1.1 equiv.), 1-iodohexane (20 
equiv.), the hexylated product was obtained as a pale 
yellow oil (43%). 1H-NMR (300 MHz, CDCl3) δ 8.26 
(s, 1H), 7.58 (q, J = 7.9 Hz, 4H), 7.50~7.34 (m, 3H), 
1.92~1.86 (m, 1H), 1.44 (s, 3H), 1.43 (s, 9H), 1.26 (m, 
8H), 0.85 (t, J = 6.6 Hz, 3H) ppm; 13C-NMR (500 MHz, CDCl3) δ 171.07, 170.07, 155.27, 
132.47, 130.01, 129.13, 126.62, 81.92, 54.00, 35.72, 31.77, 29.92, 28.10, 24.29, 22.76, 
20.12, 14.25 ppm; IR (KBr) 2928, 2857, 1774, 1734, 1591, 1459, 1369, 1255, 1147, 1070, 
913, 848, 771 cm-1; HRMS (FAB) calcd for [C21H31BrNO4]+ ([M + H]+): 440.1436, found: 
440.1428; The enantioselectivity was determined by chiral HPLC analysis (DAICEL 
Chiralcel OD-H, hexane : 2-propanol = 99 : 1, flow rate = 1.0 mL/min, 23 °C, λ = 256 nm, 
retention times; S isomer (minor) 7.4 min, R isomer (major) 8.0 min, 79% ee, []  = + 
6.19 (c 1.0, CHCl3). 
 
(S)-2-(tert-Butoxycarbonyl)-2-methylpent-4-enoic acid ((S)-105) 
In 1N KOH methanol solution (2 mL) was dissolved (R)-103b (60 
mg). After stirring for 12 h, the reaction mixture was concentrated 
in vacuo, diluted with Ethyl acetate, extracted with water and 
acidified with aqueous 1N HCl. Then aqueous layer was extracted 
with dichloromethane (10 mL x 5). Organic extreact was dried over anhydrous MgSO4, 
filtered, and concentrated in vacuo. The residue was purified by flash column 
chromatography (230~400 mesh silica gel, hexane : EtOAc = 1 : 1) to give (S)-105 (32 
mg, 98 %). Colorless oil. 1H-NMR (300 MHz, DMSO) δ 12.79 (s, 1H), 5.70 (h, J = 8.4 
Hz, 1H), 5.17~5.10 (m, 2H), 2.48 (h, J = 7.0 Hz, 2H), 1.42 (s, 9H), 1.25 (s, 3H) ppm; 13C-
NMR (500 MHz, DMSO) δ 173.07, 170.51, 133.21, 118.79, 80.54, 53.25, 27.48, 19.45 
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ppm; IR (KBr) 3461, 2982, 1712, 1643, 1460, 1394, 1255, 1150, 996, 885, 772, 687, 649 
cm-1; HRMS (FAB) calcd for [C11H19O4]+ ([M + H]+): 215.1283, found: 215.1283 
 
1-Allyl 3-(tert-butyl) (S)-2-allyl-2-methylmalonate ((S)-106) 
To the solution of (S)-105 (30 mg) in acetonitrile (1 mL) were 
added trimethylamine (59 μL, 0.42 mmol) and allyl bromide 
(24 μL, 0.28 mmol). Then heating for 8 h. After completion of 
the reaction, the reaction mixture was diluted with ethyl 
acetate (10 ml), washed with brine (5 mL x 2), dried over anhydrous MgSO4, filtered, and 
concentrated in vacuo. The residue was purified by column chromatography (230~400 
mesh silica gel, hexane : EtOAc = 40 : 1) to give (S)-106 (30 mg, 85 %). Colorless oil. 
1H-NMR (300 MHz, CDCl3) δ 5.93~5.80 (m, 1H), 5.74~5.60 (m, 1H), 5.25 (dd, J1 = 28.7 
Hz, J2 = 13.8 Hz, 2H), 5.08 (d, J = 8.2 Hz, 1H), 5.04 (s, 1H), 4.57 (d, J = 5.7 Hz, 2H), 
2.56 (d, J = 7.3 Hz, 2H), 1.40 (s, 9H), 1.33 (s, 3H) ppm; 13C-NMR (500 MHz, CDCl3) δ 
171.83, 170.64, 132.69, 131.76, 118.86, 118.32, 81.44, 65.58, 53.90, 39.98, 27.75, 19.60 
ppm; IR (KBr) 3080, 2938, 2348, 1731, 1642, 1475, 1393, 1146, 1068, 987, 921, 878, 
801, 739, 649 cm-1; HRMS (FAB) calcd for [C14H23O4]+ ([M + H]+): 255.1596, found: 
255.1596 
 
tert-Butyl (S)-3-Methyl-2-oxo-2,3,4,7-tetrahydrooxepine-3-carboxylate ((S)-107) 
To the solution of (S)-106 (30 mg) in anhydrous dichloromethane 
(12 mL) was added Grubbs’ catalyst 2nd generation (16.7 mg, 
0.012 mmol). After 3 h in reflux, excess silica gel was poured, 
filtered, and concentrated in vacuo. The residue was purified by 
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column chromatography (230~400 mesh silica gel, hexane : EtOAc = 15 : 1) to give (S)-
107 (20.9 mg, 83%). White solid (mp : 90 - 93 oC). 1H-NMR (300 MHz, CDCl3) δ 
5.72~5.61 (m, 2H), 4.82~4.70 (m, 1H), 4.28~4.20 (m, 1H), 2.75~2.66 (m, 1H), 2.32~2.21 
(m, 1H), 1.41 (s, 12H) ppm; 13C-NMR (500 MHz, CDCl3) δ 171.26, 171.07, 129.71, 
128.62, 81.64, 65.66, 54.11, 39.04, 27.84, 20.75 ppm; IR (KBr) 3052, 3022, 2860, 1851, 
1732, 1645, 1578, 1513, 1455, 1392, 1391, 1301, 1251, 1217, 1163, 1134, 1082, 1012, 
1005, 948, 848, 816, 753, 701 cm-1; HRMS (FAB) calcd for [C12H19O4]+ ([M + H]+): 
227.1283, found: 227.1283; The enantioselectivity was determined by chiral HPLC 
analysis (DAICEL Chiralpak AD-H, hexane : 2-propanol = 95 : 5, flow rate = 1.0 mL/min, 
23°C, λ = 256 nm, retention times; R isomer (minor) 7.5 min, S isomer (major) 8.7 min, 




To the solution of (R)-103a (30 mg) in dichloromethane 
(0.8 mL) was added trifluofoacetic acid (0.2 mL) at 0 °C. 
After stirring for 12 h, the reaction mixture was 
concentrated in vacuo to give (R)-107 (24 mg, 92 %). 
White solid (mp : 110 - 112 °C). 1H-NMR (300 MHz, 
DMSO) δ 13.30 (s, 1H), 8.77 (s, 1H), 7.73 (s, 4H), 
7.29~7.17 (m, 5H), 3.21 (q, J = 15.31 Hz, 2H), 1.29(s, 3H) ppm; 13C-NMR (500 MHz, 
DMSO) δ 172.23, 168.55, 156.72, 135.91, 132.18, 130.11, 129.16, 128.13, 126.85, 
125.49, 53.58, 40.35, 19.28 ppm; IR (KBr) 3197, 3029, 2938, 2601, 1741, 1562, 1455, 
1380, 1302, 1212, 1088, 970, 884, 701 cm-1; HRMS (FAB) calcd for [C18H16BrNO4]+ ([M 









(S)-2-Benzyl-3-(tert-butoxy)-2-methyl-3-oxopropanoic acid ((S)-109) 
Hydrolysis under alkali basic condition: Compound (R)-103a (60 
mg) was dissolved in 1N KOH methanol solution (2 mL). After 
stirring for 12 h, the reaction mixture was concentrated in vacuo, 
diluted with Ethyl acetate, extracted with water and acidified with 
aqueous 1N HCl. Then aqueous layer was extracted with 
dichloromethane (10 mL x 5). Organic extract was dried over anhydrous MgSO4, filtered, 
and concentrated in vacuo to give (S)-109 (35 mg, 98 %).  
Catalytic hydrogenation: To the solution of (R)-103a (60 mg) in ethanol (2 mL) was 
added Palladium/Carbon (10 mg) under atmospheric H2 gas. After 4 h stirring, the 
reaction mixture was filtered through the Celite 545 and concentrated in vacuo. The 
residue was purified by flash column chromatography (230~400 mesh silica gel, hexane : 
EtOAc = 1: 1) to give (S)-109 (34 mg, 97%). White solid (mp : 110 - 114 °C). 1H-NMR 
(300 MHz, DMSO) δ 13.30 (s, 1H), 8.77 (s, 1H), 7.73 (s, 4H), 7.29~7.17 (m, 5H), 3.21(q, 
J = 15.8 Hz, 2H), 1.30 (s, 3H) ppm; 13C-NMR (500 MHz, DMSO) δ 173.02, 170.53, 
136.52, 130.13, 127.94, 126.62, 80.76, 54.50, 40.31, 27.44, 19.31 ppm; IR (KBr) 3064, 
2980, 1711, 1605, 1496, 1394, 1370, 1255, 1154, 1031, 846, 734, 701 cm-1; HRMS (FAB) 









N-(Cyclohexylthio)phthalimide (0.6 mmol) was added to a 
solution of malonate substrate 66 (0.2mmol) and PTC 5m 
(0.02mmol) in toluene (2.0mL). At the -40°C, aq. 50% KOH 
(1.0mmol) was added to the reaction mixture and stirred until 
the starting material disappeared. EYELA PSL -1400 was used 
for low temperature stirring and the stirring rate was 7. After completion of the reaction, 
the reaction mixture was diluted with ethyl acetate (10 ml), washed with brine (5 mL x 2), 
dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was 
purified by column chromatography(silica gel 230~400mesh, hexane : EtOAc = 20 : 1) to 
afford product (92%). Pale yellow oil. 1H-NMR(300 MHz, CDCl3) δ 7.57(d, J = 8.33, 
2H), 7.45~7.29(m, 8H), 2.89~2.82(m, 1H), 1.91(t, J = 12.36, 2H), 1.66~1.63(m, 2H), 
1.53(s, 3H), 1.73~1.70(m, 1H), 1.38~1.37(m, 6H), 1.30(s, 9H) ; 13C-NMR(500 MHz, 
CDCl3) δ 168.28, 167.72, 165.59, 134.71, 132.26, 131.14, 129.97, 129.35, 129.25, 128.53, 
128.31, 82.94, 57.07, 43.18, 35.11, 27.78, 26.27, 25.57, 22.74 ; IR(KBr) 3060, 2931, 
1764, 1592, 1566, 1491, 1369, 1253, 1111, 1068, 986, 873, 780, 762, 673, 614 cm-1 ; 
HRMS(FAB) : calcd for [C27H33NO4S]+ : 467.2130, found : 468.2209. The 
enantioselectivity was determined by chiral HPLC analysis (DAICEL Chiralpak AS-H, 
hexane : 2-propanol = 99 : 1, flow rate = 1.0 mL/min, 23°C, λ = 256 nm, retention times; 
minor isomer 6.4 min, major isomer 9.6 min, 90% ee. []  = +8.5 (c 1.0, CHCl3). 
 
1-(tert-butyl) 3-(2,2-diphenylethyl) 2-methylmalonate (111) 
Following the general procedure (B). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 7.31~7.17(m, 10H), 4.67(d, J 
= 7.35Hz, 2H), 4.38(t, J = 7.59Hz, 1H), 3.25(q, J = 
7.32Hz, 1H), 1.34(s, 9H), 1.24(d, J = 7.32Hz, 3H) ; 13C-
NMR(500 MHz, CDCl3) δ 169.94, 143.12, 129.68, 
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128.29, 126.46, 82.66, 69.10, 46.08, 41.11, 28.73, 13.51 ; IR(KBr) 3902, 3840, 3734, 
3647, 3565, 2348, 2310, 1777, 1679, 1588, 1508, 1488, 1396, 1338, 1164, 1006 cm-1 ; 
HRMS(FAB) : calcd for [C22H26O4]+ : 354.1831, found : 354.1832 
 
1-(tert-butyl) 3-phenethyl 2-methylmalonate (112) 
Following the general procedure (B). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 7.23~7.19(m, 5H), 4.47(m, 
2H), 4.38(t, J = 7.59Hz, 1H), 3.25(q, J = 7.32Hz, 1H), 
2.96(m, 2H), 1.34(s, 9H), 1.24(d, J = 7.32Hz, 3H) ; 13C-
NMR(500 MHz, CDCl3) δ 169.92, 138.12, 129.68, 128.29, 125.46, 82.43, 65.10, 46.08, 
34.11, 28.73, 13.51 ; IR(KBr) 3882, 3756, 3647, 3565, 2348, 2317, 1756, 1679, 1588, 
1508, 1488, 1396, 1338, 1164, 1006 cm-1 ; HRMS(FAB) : calcd for [C16H22O4]+ : 
278.1518, found : 379.1590 
 
1-(4-bromophenethyl) 3-(tert-butyl) 2-methylmalonate (113) 
Following the general procedure (B). Colorless oil. 
1H-NMR(300 MHz, CDCl3) δ 7.59(q, J = 7.75Hz, 4H), 
4.46(m, 2H), 4.39(t, J = 7.59Hz, 1H), 3.25(q, J = 
7.32Hz, 1H), 2.96(m, 2H), 1.34(s, 9H), 1.24(d, J = 
7.32Hz, 3H) ; 13C-NMR(500 MHz, CDCl3) δ 169.19, 137.17, 131.21, 82.12, 65.12, 46.10, 
34.05, 28.35, 13.50 ; IR(KBr) 3060, 2931, 1764, 1592, 1566, 1491, 1369, 1253, 1111, 
1068, 986, 873, 780, 762, 673, 614 cm-1 ; HRMS(FAB) : calcd for [C16H21BrO4]+ : 




1-(tert-butyl) 3-(2,2-diphenylethyl) 2-benzyl-2-methylmalonate (111a) 
Following the general procedure (C). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 7.31~7.17(m, 10H), 4.67(d, J 
= 7.35Hz, 2H), 4.38(t, J = 7.59Hz, 1H), 3.25(q, J = 
7.32Hz, 1H), 1.34(s, 9H), 1.24(d, J = 7.32Hz, 3H) ; 13C-
NMR(500 MHz, CDCl3) δ 169.94, 143.12, 129.68, 
128.29, 126.46, 82.66, 69.10, 46.08, 41.11, 28.73, 13.51 ; IR(KBr) 3902, 3840, 3734, 
3647, 3565, 2348, 2310, 1777, 1679, 1588, 1508, 1488, 1396, 1338, 1164, 1006 cm-1 ; 
HRMS(FAB) : calcd for [C29H32O4]+ : 444.2301, found : 444.2302. The enantioselectivity 
was determined by chiral HPLC analysis (DAICEL Chiralcel OJ-H, hexane : 2-propanol 
= 95 : 5, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; minor 12.5 min, 
major 17.7 min, 90% ee. 
 
1-(tert-butyl) 3-phenethyl 2-benzyl-2-methylmalonate (112a) 
Following the general procedure (C). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 7.23~7.19(m, 5H), 4.47(m, 
2H), 4.38(t, J = 7.59Hz, 1H), 3.25(q, J = 7.32Hz, 1H), 
2.96(m, 2H), 1.34(s, 9H), 1.24(d, J = 7.32Hz, 3H) ; 13C-
NMR(500 MHz, CDCl3) δ 169.92, 138.12, 129.68, 
128.29, 125.46, 82.43, 65.10, 46.08, 34.11, 28.73, 13.51 ; IR(KBr) 3882, 3756, 3647, 
3565, 2348, 2317, 1756, 1679, 1588, 1508, 1488, 1396, 1338, 1164, 1006 cm-1 ; 
HRMS(FAB) : calcd for [C23H28O4]+ : 368.1988, found : 368.1989. The enantioselectivity 
was determined by chiral HPLC analysis (DAICEL Chiralcel OJ-H, hexane : 2-propanol 
= 99 : 1, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; minor 12.1 min, 
major 9.7 min, 81% ee. 
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1-(4-bromophenethyl) 3-(tert-butyl) 2-benzyl-2-methylmalonate (113a) 
Following the general procedure (C). Colorless oil. 
1H-NMR(300 MHz, CDCl3) δ 7.59(q, J = 7.75Hz, 
4H), 4.46(m, 2H), 4.39(t, J = 7.59Hz, 1H), 3.25(q, J 
= 7.32Hz, 1H), 2.96(m, 2H), 1.34(s, 9H), 1.24(d, J = 
7.32Hz, 3H) ; 13C-NMR(500 MHz, CDCl3) δ 169.19, 
137.17, 131.21, 82.12, 65.12, 46.10, 34.05, 28.35, 13.50 ; IR(KBr) 3060, 2931, 1764, 
1592, 1566, 1491, 1369, 1253, 1111, 1068, 986, 873, 780, 762, 614 cm-1 ; HRMS(FAB) : 
calcd for [C23H27BrO4]+ : 446.1093, found : 446.1094. The enantioselectivity was 
determined by chiral HPLC analysis (DAICEL Chiralcel OJ-H, hexane : 2-propanol = 99 : 
1, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; minor 15.4 min, major 




Following the general procedure (C). White solid (mp : 
42.2 oC). 1H-NMR(300 MHz, CDCl3) δ 7.55(d, J = 7.14Hz, 
2H), 7.40~7.22(m, 8H), 5.64~5.50(m, 1H), 5.00(s, 1H), 
4.95(d, J = 8.43Hz, 1H), 2.42(h, J = 6.90Hz, 2H), 1.26(s, 
9H), 1.21(s, 3H) ; 13C-NMR(400 MHz, CDCl3) δ 169.99, 
169.16, 165.26, 134.44, 132.43, 132.28, 130.92, 129.61, 128.99, 128.64, 128.31, 128.11, 
119.01, 81.67, 53.50, 39.91, 27.66, 19.57 ; IR(KBr) 3748, 3063, 2979, 2933,1774, 1734, 
1593, 1491, 1446, 1369, 1324, 1253, 1147, 1090, 989, 697 cm-1 ; HRMS(FAB) : calcd for 
[C28H29NO4]+ : 443.2097, found : 443.2098. The enantioselectivity was determined by 
chiral HPLC analysis (DAICEL Chiralpak AD-H, hexane : 2-propanol = 99 : 1, flow rate 
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= 1.0 mL/min, 23 oC, λ = 256 nm, retention times; minor 22.4 min, major 27.6 min, 88% 
ee. 
 
tert-butyl (E)-2-benzyl-3-[(benzylideneamino)oxy]-2-methyl-3-oxopropanoate (95a) 
Following the general procedure (C). White solid. 1H-
NMR(300 MHz, CDCl3) δ 8.31(s, 1H), 7.72(d, J = 6.42Hz, 
2H), 7.49~7.38(m, 3H), 1.44(s, 3H), 1.43(s, 9H) ; 13C-
NMR(500 MHz, CDCl3) δ 170.22, 169.40, 156.24, 132.34, 
131.80, 129.84, 128.87, 128.44, 119.33, 81.89, 53.36, 
40.05, 27.84, 19.75 ; IR(KBr) 3862, 3748, 1078, 2980, 1774, 1734, 1641, 1613, 1575, 
1508, 1450, 1370, 1253, 1209, 1146, 1089, 995, 917, 846, 757, 693 cm-1 ; HRMS(FAB) : 
calcd for [C22H25NO4]+ : 367.1784, found : 367.1785. The enantioselectivity was 
determined by chiral HPLC analysis (DAICEL Chiralcel OJ-H, hexane : 2-propanol = 90 : 
10, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; minor 11.7 min, major 
9.9 min, 82% ee. 
 
1-(tert-butyl) 3-(3-phenylpropyl) 2-methylmalonate (115) 
Following the general procedure (B). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 7.23~7.19(m, 5H), 4.47(m, 
2H), 4.38(t, J = 7.59Hz, 1H), 3.25(q, J = 7.32Hz, 1H), 
2.96(m, 2H), 1.34(s, 9H), 1.24(d, J = 7.32Hz, 3H) ; 13C-
NMR(500 MHz, CDCl3) δ 169.92, 138.12, 129.68, 128.29, 125.46, 82.43, 65.10, 46.08, 
34.11, 28.73, 13.51 ; IR(KBr) 3882, 3756, 3647, 3565, 2348, 2317, 1756, 1679, 1588, 
1508, 1488, 1396, 1338, 1164, 1006 cm-1 ; HRMS(FAB) : calcd for [C17H24O4]+ : 
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292.1675, found : 292.1675 
 
1-(tert-butyl) 3-(4-phenylbutyl) 2-methylmalonate (116) 
Following the general procedure (B). Colorless oil. 
1H-NMR(300 MHz, CDCl3) δ 7.23~7.19(m, 5H), 
4.47(m, 2H), 4.38(t, J = 7.59Hz, 1H), 3.25(q, J = 
7.32Hz, 1H), 2.96(m, 2H), 1.34(s, 9H), 1.24(d, J = 
7.32Hz, 3H) ; 13C-NMR(500 MHz, CDCl3) δ 169.92, 138.12, 129.68, 128.29, 125.46, 
82.43, 65.10, 46.08, 34.11, 28.73, 13.51 ; IR(KBr) 3882, 3756, 3647, 3565, 2348, 2317, 
1756, 1679, 1588, 1508, 1488, 1396, 1338, 1164, 1006 cm-1 ; HRMS(FAB) : calcd for 
[C18H26O4]+ : 306.1831, found : 306.1832 
 
1-(tert-butyl) 3-(3-phenylpropyl) 2-benzyl-2-methylmalonate (115a) 
Following the general procedure (C). Colorless oil. 1H-
NMR(300 MHz, CDCl3) δ 7.23~7.19(m, 5H), 4.47(m, 
2H), 4.38(t, J = 7.59Hz, 1H), 3.25(q, J = 7.32Hz, 1H), 
2.96(m, 2H), 1.34(s, 9H), 1.24(d, J = 7.32Hz, 3H) ; 13C-
NMR(500 MHz, CDCl3) δ 169.92, 138.12, 129.68, 
128.29, 125.46, 82.43, 65.10, 46.08, 34.11, 28.73, 13.51 ; IR(KBr) 3882, 3756, 3647, 
3565, 2348, 2317, 1756, 1679, 1588, 1508, 1488, 1396, 1338, 1164, 1006 cm-1 ; 
HRMS(FAB) : calcd for [C24H30O4]+ : 382.2144, found : 382.2145. The enantioselectivity 
was determined by chiral HPLC analysis (DAICEL Chiralpak AD-H, hexane : 2-propanol 
= 99 : 1, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; minor 5.0 min, 
major 5.5 min, 45% ee. 
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1-(tert-butyl) 3-(4-phenylbutyl) 2-benzyl-2-methylmalonate (116a) 
Following the general procedure (C). Colorless oil. 
1H-NMR(300 MHz, CDCl3) δ 7.23~7.19(m, 5H), 
4.47(m, 2H), 4.38(t, J = 7.59Hz, 1H), 3.25(q, J = 
7.32Hz, 1H), 2.96(m, 2H), 1.34(s, 9H), 1.24(d, J = 
7.32Hz, 3H) ; 13C-NMR(500 MHz, CDCl3) δ 169.92, 
138.12, 129.68, 128.29, 125.46, 82.43, 65.10, 46.08, 34.11, 28.73, 13.51 ; IR(KBr) 3882, 
3756, 3647, 3565, 2348, 2317, 1756, 1679, 1588, 1508, 1488, 1396, 1338, 1164, 1006 
cm-1 ; HRMS(FAB) : calcd for [C25H32O4]+ : 396.2301, found : 396.2303. The 
enantioselectivity was determined by chiral HPLC analysis (DAICEL Chiralcel OD-H, 
hexane : 2-propanol = 99 : 1, flow rate = 1.0 mL/min, 23 oC, λ = 256 nm, retention times; 
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상전이 촉매반응은 하나의 상에 있는 반응물을 반응이 일어나는 다른 상으
로 옮겨주어 반응을 촉진시키는 촉매반응이다. 이 때 일반적으로 반응물이 있
는 상은 수층이고, 다른 상은 유기층이다. 상전이 촉매, PTC라 불리는 이 촉
매는 두 층을 왕복하며 반응을 촉진시킨다. 그렇기 때문에 PTC는 암모늄 같
은 친수성 분자구조와 탄화수소 같은 친유성 분자구조를 동시에 갖는다. 반응
은 섞이지 않는 불균일한 두 개의 상에서 진행되는데, 이는 균일한 하나의 상
에서 진행되던 기존의 방법론에는 없었던 장점들이 생기게 한다. 또한 이는 
실험실에서부터 공장에 이르기까지 다양한 규모의 반응에서 매우 넓은 적용틀
을 제공한다. 말론산은 직선형의 3개의 탄소가 양 끝의 산화수는 +3이며 가
운데는 -2인 구조이다. 이러한 특성 덕분에 여러 반응 – 마이클 첨가반응, 프
리델 크라프츠 알킬화 반응, 고리화 반응, 크뇌베나겔 축합, 고리프로판화 반
응, 고리화첨가 반응, 딜스-알더 반응 등이 말론산에 적용가능하다. 그래서 
말론산은 전합성, 방법론, 의약화학 같은 다양한 연구분야에서 가장 기본적인 
시작물질 중 하나가 될 수 있다. 특히, 말론산의 알파 위치에 카이랄성이 부
여되면, 매우 유용한 카이랄 구성 단위가 될 수 있다. 
2011년 본 연구실은 이페닐메틸 삼차-부틸 말론산을 기질로 상전이 촉매 
알킬화를 통해 알파,알파-이알킬말론산의 높은 수준의 입체선택적인 합성을 
보고했다. 이 결과는 매우 높은 수율과 거울상 초과량을 보여주었다. 하지만, 
산 조건에서는 양쪽 에스터가 모두 가수분해되어 알파의 카이랄성이 사라지고
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염기 조건에서는 아무 반응도 일어나지 않는다는 선택적인 가수분해의 문제가 
있었다.. 본 연구실은 선택적 가수분해 측면에서 개선된 기질인 2-메틸벤질 
삼차-부틸 말론산을 개발하였고, 이는 염기 조건에서 선택적인 가수분해가 
가능하였다. 하지만 산 조건에서는 양쪽 에스터가 모두 가수분해 되었으며, 
알킬화는 상대적으로 낮은 입체선택성과 긴 반응시간을 보여주었다. 양쪽 조
건에서의 선택적 가수분해와 매우 높은 반응성 및 입체선택성을 위해, 본 연
구실은 O’donnell 기질에서 유래한 구조인 이페닐메틸이민을 가진 벤질리딘아
미노 삼차-부틸 말론산을 설계했다. 최적화 후, (E)-4-브로모벤질리딘아미
노 삼차 말론산을 기질로 하여 알파,알파-이알킬말론산을 높은 화학수율과 
(최대 97%) 광학수율로 (최대 98%) 얻을 수 있었다. 그 적용으로서 알릴화 
생성물을 염기에서의 선택적 가수분해 후 알릴 에스터를 만들어 복분해를 통
해 7원환 락톤을 만들었고, 벤질화 생성물에서 산과 염기 양쪽 조건에서의 훌
륭한 선택적 가수분해를 보였다. 또한 염기 조건에서의 생성물은 수소 기체 
하에서 접촉환원을 통해서도 얻을 수 있었다. 후속 연구로서, 이페닐메틸리딘
아미노 삼차-부틸 말론산을 기질로 하여 입체선택적인 상전이 촉매 황화반응
을 90%의 높은 화학수율 92%라는 높은 광학수율로 달성했다. 그리고 대표적
인 벤질리딘아미노 말론산의 단순화와 탄소수 다양화 말론산를 통해 변형된 
말론산의 비대칭 상전이 촉매 알킬화에서 카이랄 유도의 변화를 관찰했다. 
본 연구자가 도출한 상기의 연구결과들은 선택적인 가수분해가 가능한 비대
칭 말론산을 구축하는 새로운 합성법으로서 의의가 있다. 본 반응을 통하여 4
차 탄소를 가진 카이랄 분자의 합성에 필요한 카이랄 구조 단위를 설계하는데 
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큰 도움을 줄 수 있을 것으로 예상된다. 
 
주요어 : 비대칭 합성, 상전이 촉매 알킬화 반응, 벤질리딘아미노, 알파,알파-
이알킬말론산, 선택적 가수분해, 비대칭 4차 탄소 
 


















1H-NMR of compound (300 MHz, DMSO) 
 




1H-NMR of compound 5m (300 MHz, DMSO) 
 




1H-NMR of compound 68 (300 MHz, CDCl3) 
 




1H-NMR of compound 70 (300 MHz, DMSO) 
 




1H-NMR of compound 83 (300 MHz, DMSO) 
 




1H-NMR of compound 84 (300 MHz, DMSO) 
 
13C-NMR of compound 84 (300 MHz, DMSO) 
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1H-NMR of compound 85 (300 MHz, DMSO) 
 




1H-NMR of compound 86 (300 MHz, DMSO) 
 




1H-NMR of compound 87 (300 MHz, DMSO) 
 




1H-NMR of compound 88 (300 MHz, DMSO) 
 












1H-NMR of compound 90 (300 MHz, DMSO) 
 












1H-NMR of compound 90 (300 MHz, DMSO) 
 












1H-NMR of compound 91 (300 MHz, DMSO) 
 




1H-NMR of compound 92 (300 MHz, DMSO) 
 




1H-NMR of compound 93 (300 MHz, DMSO) 
 




1H-NMR of compound 66 (300 MHz, CDCl3) 
 




1H-NMR of compound 94 (300 MHz, CDCl3) 
 




1H-NMR of compound 95 (300 MHz, CDCl3) 
 




1H-NMR of compound 96 (300 MHz, CDCl3) 
 


















1H-NMR of compound 97 (300 MHz, CDCl3) 
 


















1H-NMR of compound 98 (300 MHz, CDCl3) 
 




1H-NMR of compound 99 (300 MHz, CDCl3) 
 




1H-NMR of compound 100 (300 MHz, CDCl3) 
 




1H-NMR of compound 101 (300 MHz, CDCl3) 
 




1H-NMR of compound 102 (300 MHz, CDCl3) 
 




1H-NMR of compound 103 (300 MHz, CDCl3) 
 




1H-NMR of compound 104 (300 MHz, CDCl3) 
 




1H-NMR of compound 66b (300 MHz, CDCl3) 
 




1H-NMR of compound 94b (300 MHz, CDCl3) 
 




1H-NMR of compound 95b (300 MHz, CDCl3) 
 




1H-NMR of compound 96b (300 MHz, CDCl3) 
 




1H-NMR of compound 97b (300 MHz, CDCl3) 
 




1H-NMR of compound 98b (300 MHz, CDCl3)  
 




1H-NMR of compound 99b (300 MHz, CDCl3) 
 




1H-NMR of compound 100b (300 MHz, CDCl3) 
 




1H-NMR of compound 101b (300 MHz, CDCl3) 
 




1H-NMR of compound 102b (300 MHz, CDCl3) 
 




1H-NMR of compound 103b (300 MHz, CDCl3) 
 




1H-NMR of compound 104b (300 MHz, CDCl3) 
 




1H-NMR of compound 103a (300 MHz, CDCl3) 
 




1H-NMR of compound 103c (300 MHz, CDCl3) 
 






















1H-NMR of compound 103d (300 MHz, CDCl3) 
 






















1H-NMR of compound 103e (300 MHz, CDCl3) 
 




1H-NMR of compound 103f (300 MHz, CDCl3) 
 




1H-NMR of compound 103g (300 MHz, CDCl3) 
 






















1H-NMR of compound 103h (300 MHz, CDCl3) 
 




1H-NMR of compound 103i (300 MHz, CDCl3) 
 




1H-NMR of compound 103j (300 MHz, CDCl3) 
 




1H-NMR of compound 103k (500 MHz, CDCl3) 
 




1H-NMR of compound 103l (300 MHz, CDCl3) 
 




1H-NMR of compound 103m (300 MHz, CDCl3) 
 




1H-NMR of compound 103n (300 MHz, CDCl3) 
 



















1H-NMR of compound 103o (300 MHz, CDCl3) 
 




1H-NMR of compound (S)-105 (300 MHz, DMSO) 
 




1H-NMR of compound (S)-106 (300 MHz, CDCl3) 
 




1H-NMR of compound (S)-107 (300 MHz, CDCl3) 
 














1H-NMR of compound (R)-108 (300 MHz, DMSO) 
 
13C-NMR of compound (R)-108 (500 MHz, DMSO) 
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1H-NMR of compound (S)-109 (300 MHz, DMSO) 
 




1H-NMR of compound 110 (300MHz, CDCl3) 
 
13C-NMR of compound 110 (500MHz, CDCl3) 
 
